 |
Education Sessions | Lunch Debates
| ESH-EHA Joint Symposium | Poster
Session 1 | Satellite Symposia
EDUCATION SESSION
08.00 - 09.30 and 13.15 - 14.45,
Room Le Mont-Blanc / Le Cervin (Geneva Palexpo)
| Chair: |
R. Hehlmann (Medical Hospital Mannheim, Mannheim,
Germany) |
 |
A EUROPEAN NETWORK
FOR AML
A.K. Burnett (University Hospital Wales, Cardiff, Wales, United
Kingdom) |
| |
DEVELOPING A EUROPEAN NETWORK
FOR ADULT ALL
N. Gökbuget (University of Frankfurt, Frankfurt, Germany)
|
| |
THE NEED FOR EUROPEAN STANDARDS
IN GENE EXPRESSION PROFILES IN AML
B.D. Young (Cancer Research UK, London, United Kingdom) |
EDUCATION SESSION
08.00 - 09.30 and 13.15 - 14.45, Room Le Jura (Geneva Palexpo)
| Chair: |
C. Cordonnier (Henri Mondor Hospital, Créteil,
France) |
| |
THE CHOICE OF
EMPIRICAL THERAPY AND PROPHYLAXIS
A. Del Favero (University of Perugia, Perugia, Italy) |
| |
FUNGAL INFECTIONS: CURRENT
DIAGNOSIS AND TREATMENT
C. Cordonnier (Henri Mondor Hospital, Créteil, France)
|
| |
VIRAL INFECTIONS: CURRENT
DIAGNOSIS AND TREATMENT
P. Ljungman (Karolinska Institute, Stockholm, Sweden) |
EDUCATION SESSION
08.00 - 09.30 and 13.15 - 14.45, Room D (Geneva Palexpo)
| Chair: |
J. Koistinen (Finnish Red Cross Blood Transfusion
Service, Helsinki, Finland) |
| |
EVOLUTION OF
MICROBIAL SAFETY
J. Barbara (National Blood Service, London, United Kingdom)
|
| |
HAEMOVIGILANCE PROCEDURE
IN TRANSFUSION MEDICINE
J.C. Faber (Luxembourg Red Cross, Luxembourg, Luxembourg) |
| |
SAFETY ASPECTS OF BLOOD TRANSFUSION
AND EUROPEAN LEGISLATION
J. Koistinen (Finnish Red Cross Blood Transfusion Service, Helsinki,
Finland) |
|
|
EDUCATION SESSION
08.00 - 09.30 and 13.15 - 14.45, Room H (Geneva Palexpo)
| Chair: |
A. Madrigal (The Anthony Nolan Research Institute,
London, United Kingdom) |
| |
IMMUNOTHERAPY
WITH ALLOREACTIVE NATURAL KILLER CELLS IN HAPLOIDENTICAL HEMATOPOIETIC
TRANSPLANTATION
A. Velardi (Univeristy of Perugia, Perugia, Italy) |
| |
IMMUNOTHERAPY WITH ALLOREACTIVE
T-CELLS
A. Madrigal (The Anthony Nolan Research Institute, London,
United Kingdom) |
| |
IMMUNOTHERAPY OF HEMATOLOGICAL
MALIGNANCIES WITH DENDRITIC CELLS
J.H.F. Falkenburg (University Medical Center Leiden, Leiden,
The Netherlands) |
EDUCATION SESSION
08.00 - 09.30 and 13.15 - 14.45, Room E (Geneva Palexpo)
| Chair: |
M. Cazzola (University of Pavia Medical School,
Pavia, Italy) |
| |
ERYTHROPOIETIN
PATHOPHYSIOLOGY AND ERYTHROPOIETIN DEFICIENCY ANEMIA
M. Cazzola (University of Pavia Medical School, Pavia, Italy)
|
| |
EPOETIN-INDUCED AUTOIMMUNE
PURE RED CELL APLASIA
N. Casadevall (Hôpital Hôtel-Dieu, Paris, France)
|
| |
ERYTHROPOIETIN & ERYTHROPOIESIS:
POLYCYTHEMIAS DUE TO DISRUPTION OF OXYGEN HOMEOSTASIS
J.T. Prchal (Baylor College of Medicine, Houston, USA) |
|
EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45, Room A (Geneva Palexpo)
| Chair: |
W. Fibbe (Leiden University Medical Centre, Leiden,
The Netherlands) |
| |
NUCLEAR TRANSPLANTATION,
EMBRYONIC STEM CELLS AND THE POTENTIAL FOR CELL THERAPY
K. Hochedlinger (Whitehead Institute, Cambridge, USA) |
| |
THE MOLECULAR BASIS OF STEM
CELL SELF RENEWAL
J. Krosl (Université de Montréal, Montreal, Canada) |
| |
THE ROLE OF BONE MARROW STEM
CELLS IN TISSUE VASCULARIZATION
S. Rafii (Cornell University Medical College, New York, NY,
USA) |
EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45, Room B (Geneva Palexpo)
| Chair: |
R. Skoda (Basel University Hospital, Basel, Switzerland) |
| |
CHRONIC MYELOPROLIFERATIVE
DISORDERS: MOLECULAR MARKERS AND PATHOGENESIS
R. Skoda (Basel University Hospitals, Basel, Switzerland) |
| |
MANAGEMENT OF THE MYELOPROLIFERATIVE
DISORDERS: DISTINGUISHING DATA FROM DOGMA
A.R. Green (Cambridge Institute for Medical Research, Cambridge,
United Kingdom) |
| |
FIP1L1-PDGFR _ IN HYPEREOSINOPHILIC
SYNDROME AND MASTOCYTOSIS
G. Gilliland (Harvard Institute of Medicine, Boston, USA) |
EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45, Room C (Geneva Palexpo)
| Chair: |
Ch. Willman (University of New Mexico, Albuquerque,
NM, USA) |
| |
BIOINFORMATICS
J. Quackenbush (The Institute for Genomic Research, Rockville,
MD, USA) |
| |
PROTEOMICS
D. Hochstrasser (Geneva University Hospital, Geneva, Switzerland) |
| |
FROM LEUKEMIA GENOMICS TO
PROGNOSTIC AND THERAPEUTIC TARGET VALIDATION
Ch. Willman (University of New Mexico, Albuquerque, NM, USA) |
|
|
EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45,
Room Le Mont-Blanc / Le Cervin (Geneva Palexpo)
| Chair: |
B. Coiffier (Centre Hospitalier Lyon-Sud, Pierre
Benité, France) |
| |
THE MOLECULAR
HETEROGENEITY OF DIFFUSE LARGE B CELL LYMPHOMA
R. Gascoyne (BC Cancer Agency, Vancouver BC, Canada) |
| |
PET SCAN IN THE THERAPEUTIC
STRATEGY
C. Haioun (Hôpital Henri Mondor, Creteil, France) |
| |
DOSE INTENSITY OR MONOCLONAL
ANTIBODIES IN FIRST LINE TREATMENT
B. Coiffier (Centre Hospitalier Lyon-Sud, Pierre Benité,
France) |
EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45, Room Le Jura (Geneva Palexpo)
| Chair: |
K.J. Clemetson (Theodor-Kocher-Institut der Universität,
Bern, Switzerland) |
| |
PLATELET RECEPTOR
SIGNALLING
K.J. Clemetson (Theodor-Kocher-Institut der Universität,
Bern,
Switzerland) |
| |
MEASURING PLATELET FUNCTION?
P. Harrison (Churchill Hospital, Oxford, United Kingdom) |
| |
ANTIPLATELET AGENTS
M. Cattaneo (University of Milano, Milano, Italy) |
EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45, Room D (Geneva Palexpo)
| Chair: |
M. Contreras (Blood Transfusion Centre, London,
United Kingdom) |
| |
HAEMOVIGILANCE
IN THE UNITED KINGDOM AND EUROPE
D. Stainsby (National Blood Service Newcastle, Newcastle, United
Kingdom) |
| |
INTRAVENOUS IMMUNOGLOBULINS
- TOO MANY INDICATIONS?
U. Nydegger (Univeristy Hospital Bern, Bern, Switzerland) |
| |
GRANULOCYTE TRANSFUSIONS
- ARE THEY EFFECTIVE?
T. Price (Puget Sound Blood Center, Seattle, USA) |
|
EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45, Room H (Geneva Palexpo)
| Chair: |
J. Melo (Imperial College London, London, United
Kingdom) |
| |
SWITCHING OFF
ONCOGENIC SIGNALS IN CHRONIC MYELOID LEUKAEMIA
J. Melo (Imperial College London, London, United Kingdom) |
| |
RNA INTERFERENCE AS POWERFUL
TOOL FOR GENE SILENCING
A. Borkhardt (Dr. Von Haunersches Kinderspital, Munich, Germany) |
| |
FLT3 TYROSINE KINASE AS A
TARGET IN ACUTE LEUKEMIAS
J. Griffin (Dana Farber Cancer Institute, Boston, USA) |
EDUCATION SESSION
10.00 - 11.30 and 15.15 - 16.45, Room E (Geneva Palexpo)
| Chair: |
D. Loukopoulos (Foundation For Biomedical Reseach,
Athens, Greece) |
| |
CONGENITAL DYSERYTHROPOIETIC
ANEMIAS
G. Tchernia (Laboratoire d’Hématologie, Le Kremlin-Bicêtre,
France) |
| |
VASO-OCCLUSION IN SICKLE-CELL
ANEMIA: ROLE OF INTERACTIONS BETWEEN BLOOD CELLS AND ENDOTHELIUM
J. Elion (Hôpital R. Debré, Paris, France) |
| |
MOLECULAR PATHOLOGY OF THALASSEMIA
INTERMEDIA
Ph. Beris (Hôpital Cantonal Universitaire, Geneva, Switzerland) |
|
|
LUNCH DEBATE
11.45 - 12.45, Room A (Geneva Palexpo)
| Chair: |
W.R. Mayr (University of Vienna, Vienna, Austria) |
| |
YES
M. Contreras (Blood Transfusion Centre, London, United Kingdom)
|
| |
NO
G. Birgegard (University of Uppsala, Uppsala, Sweden) |
LUNCH DEBATE
11.45 - 12.45, Room C (Geneva Palexpo)
| Chair: |
I. Pabinger (Medical Clinic I, Vienna, Austria) |
| |
YES
C. Negrier (Hôpital Edouard Herriot, Lyon, France) |
| |
NO
P. Giangrande (Churchill Hospital, Oxford, United Kingdom) |
LUNCH DEBATE
11.45 - 12.45, Room Le Mont-Blanc / Le Cervin (Geneva Palexpo)
| Chair: |
A. Hagenbeek (University Medical Center Utrecht,
Utrecht, the Netherlands) |
| |
YES
G. Salles (Centre Hospitalier Lyon-Sud, Pierre Benité,
France) |
| |
NO
R. Marcus (Addenbrookes Hospital, Cambridge, United Kingdom)
|
|
ESH-EHA JOINT SYMPOSIUM
11.30 – 13.00, Room D (Geneva Palexpo)
CONFLICTS AND COMPROMISES IN
THE MANAGEMENT OF PATIENTS PURSUING COMPLEMENTARY THERAPIES; AN INTERACTIVE
SESSION FOR HAEMATOLOGISTS
| Chair: |
S. Johnson (Taunton, United Kingdom) |
Discrepancies in the conceptual framework with which doctors and patients
view illness are a major source of difficulties in communication and
in the satisfactory delivery of both specific medical treatments and
broader types of health care. While it is possible to train doctors
in the skills required to be able to communicate well with patients,
little attention has been paid to examining the basic concepts with
which patients understand the physical conditions from which they
suffer. As a consequence it is often difficult to achieve a level
of mutual understanding of medical problems which, if present, would
be a sound basis for a partnership in the delivery of medical treatments.
This degree of understanding of the underlying mechanisms of disease
is one which is needed if patients are to be in a position to engage
realistically in decisions about treatment choice – for instance
in making the transition from active to palliative treatment approaches.
The current emphasis on obtaining informed consent to treatment in
a context of providing comprehensive information to patients is also
clearly dependent on a sound appreciation of the extent and limits
within which patients
understand disease processes.
The perception patients have of their illness and appropriate treatment
may also be significantly affected by conceptual frameworks which
are likely to have a profound impact on the management of their disease.
The assertion of Jehovah’s Witnesses that transfusion of blood
or blood products is precluded by their religious beliefs is a recurrent
difficulty for clinicians approaching many clinical situations but
it is especially difficult when it impacts on the management of haematological
malignancies. Patients are also increasingly willing to explore a
wide range of complementary therapies which they may encounter through
Internet searches or more direct contact with alternative therapists.
It is understandable that patients should seek any means of improving
their chances of cure, but the concurrent provision of conventional
therapy and treatment based on unconventional interpretations
of the disease process may present very significant problems. It is
sometimes difficult to negotiate with the patient and persuade them
to accept established forms of treatment in the face of objections
from the alternative therapist to the language and scientific basis
on which medical therapy is
based.
Faculty
S. Johnson (Taunton, United Kingdom)
A. Cucuianu (Cluj Romania)
P. Brice (Paris, France)
A. Kiss (Basel, Switzerland
C. Rudin (Exeter, United Kingdom) |
|
| |
WELCOME: AIM
OF MEETING
S. Johnson (Taunton, United Kingdom) |
| |
RULES OF ENGAGEMENT
S. Johnson (Taunton, United Kingdom) |
Case Study
A 32-year-old woman (a single mother with an 8-year-old son) was diagnosed
eighteen months ago with diffuse large B-cell lymphoma IPI=3. She
entered remission after six cycles of CHOP but relapsed in abdominal
lymph nodes within six months. At this point she received two cycles
of ifosfamide-based salvage chemotherapy with concurrent rituximab;
the
disease proved to be chemosensitive and she proceeded to a BEAM autograft
with six post-transplant doses of rituximab. Despite her apparent
complete remission after high-dose therapy she has had some recurrence
of her initial symptoms of fatigue and night sweats. A CT scan now
shows progression of her abdominal lymph nodes, with compression of
the left
ureter and hydronephrosis on that side. You intend to discuss the
role of active palliation with her and explore entry into a Phase
II trial involving gemcitabine and vinorelbine (she has no full siblings
and because of her ethnic group a preliminary donor search has not
revealed a good match on the national panel). She has come to Clinic
for confirmation of the CT result and to discuss treatment with you,
but is accompanied by her REIKI therapist whom you
have not met previously.
| |
CLINICAL CONSULTATION
A. Cucuianu (Cluj, Romania) |
| |
DISCUSSION AND FEEDBACK
S. Johnson (Taunton, United Kingdom) |
| |
CLINICAL CONSULTATION
P. Brice (Paris, France) |
|
DISCUSSION AND FEEDBACK
S. Johnson (Taunton, United Kingdom) |
|
THE WIDER IMPLICATIONS: INSIGHTS
FROM MEDICAL ANTHROPOLOGY AND PSYCHO-SOMATIC MEDICINE
A. Kiss (Basel, Switzerland) and C. Rudin (Exeter, United Kingdom) |
|
CONCLUSIONS
S. Johnson (Taunton, United Kingdom) |
|
SATELLITE SYMPOSIUM SUPPORTED BY ROCHE, NAPP, MUNDIPHARMA, SUPERGEN
INC., BIOENVISION AND ORTHO BIOTECH, A DIVISION OF JANSSEN-CILAG
18:30 – 20:30, Room B (Geneva Palexpo)
| Chair: |
M. Keating (The University of Texas M.D. Anderson
Cancer Center, Houston, Texas, USA) |
| |
18:30 – 18:50 |
| |
NEW DRUG DEVELOPMENT IN HEMATOLOGIC
MALIGNANCIES
S. O’Brien (The University of Texas, M.D. Anderson Cancer
Center, Houston, Texas, USA) |
| |
18:50 – 19:10 |
| |
INNOVATION IN THE MANAGEMENT OF AML AND
ALL
H. Kantarjian (The University of Texas, M.D. Anderson Cancer
Center, Houston, Texas, USA) |
| |
19:10 – 19:30 |
| |
EMERGING THERAPIES FOR CHRONIC LYMPHOCYTIC
LEUKEMIA
M. Keating (The University of Texas, M.D. Anderson Cancer Center,
Houston, Texas, USA) |
| |
19:30 – 19:50 |
| |
NOVEL APPROACHES TO PH-POSITIVE DISEASE
J. Cortes (The University of Texas, M.D. Anderson Cancer Center,
Houston, Texas, USA) |
| |
19:50 – 20:10 |
| |
NEW TARGETS TO APPROACH, OLD PATHWAYS
TO EXPLOIT
W. Plunkett (The University of Texas, M.D. Anderson Cancer Center,
Houston, Texas, USA) |
| |
20:10 – 20:30 |
|
INNOVATIVE APPROACHES TO THE TREATMENT
OF LYMPHOMA
A. Goy (The University of Texas, M.D. Anderson Cancer Center,
Houston, Texas, USA) |
|
|
SATELLITE SYMPOSIUM SUPPORTED BY PHARMION LTD
18:30 – 20:30, Room La Saleve (Geneva Palexpo)
| Chair: |
P. Fenaux (Hôpital Avicenne, Service d’hematologie
clinique, Bobigny, France) |
| |
18:30 – 18:35 |
| |
CHAIRMAN’S INTRODUCTION
P. Fenaux (Hôpital Avicenne, Service d’hematologie
clinique, Bobigny, France) |
| |
18:35 – 19:00 |
| |
EPIGENETICS: DNA HYPERMETHYLATION AND
GENE SILENCING
J. Herman (The Sidney Kimmel, Comprehensive Cancer Center, Johns
Hopkins Comprehensive Cancer Center, Baltimore, Maryland, USA) |
| |
19:00 – 19:10 |
| |
QUESTIONS AND ANSWERS |
| |
19:10 – 19:30 |
| |
MDS: CURRENT TREATMENT OPTIONS
G. Mufti (Guy’s King’s and St. Thomas’
School of Medicine, London, United Kingdom) |
| |
19:30 – 19:55 |
| |
DEMETHYLATING AGENTS IN MDS: AZACITIDINE
UPDATE
P. Fenaux (Hôpital Avicenne, Service d’hematologie
clinique, Bobigny, France) |
| |
19:55 – 20:15 |
|
AML IN THE ELDERLY PATIENT: MOLECULARLY
TARGETED THERAPIES
A.K. Burnett (University Hospital of Wales, Healthcare NHS Trust,
Cardiff, United Kingdom) |
| |
20:15 – 20:25 |
|
QUESTIONS AND ANSWERS |
| |
20:25 – 20:30 |
|
CLOSING COMMENTS
P. Fenaux (Hôpital Avicenne, Service d’hematologie
clinique, Bobigny, France) |
| |
20:30 |
|
BUFFET DINNER |
|
POSTER SESSION I
17:00 - 18:30, Hall I (Geneva Palexpo)
| |
Lymphoma: Biological aspects and
prognosis |
| |
Lymphoma: Treatment with monoclonal antibodies |
| |
Multiple Myeloma: Biological aspects |
|
ALL: Biology |
|
CLL: ZAP-70 and other markers mutational status |
|
CLL: Therapy |
|
AML Therapy |
|
Chronic Myeloid Leukemia |
|
Stem cell transplantation - Experimental |
|
Stem cell transplantation - Autologous |
|
Anticoagulation and thrombophilia |
|
Infectious complication |
|
Immune thrombocytopenic purpura |
|
Transfusion medicine and immunohematology |
|
Genetics lymphoid malignancies |
|
Cytokines / Growth factors |
|
Stem cells |
|
Genetic Leukemia I |
|
Genetic Leukemia II |
|
Anemia - Congenital |
|
Anemia - Thalassemias |
NEW THIS YEAR: “POSTER-WALKS”
 |
Unique full-three-day display
of all posters |
| |
Poster walks will be organized during the
official poster sessions.
Authors are requested to be present at the first poster
of their poster
session, at the beginning of the presentation time, to
attend the
“Poster-walks”. During these
walks, an expert in the field will discuss
posters in the same poster session. Moderators and poster
authors
will present and discuss each poster in a certain session,
together
with interested Congress participants. |
|
CD10 AND BCL-2
EXPRESSION COMBINED WITH THE INTERNATIONAL PROGNOSTIC INDEX
CAN IDENTIFY SUBGROUPS OF PATIENTS WITH DIFFUSE LARGE-CELL LYMPHOMA
WITH VERY LOW AND VERY HIGH RISK
I. Biasoli, J.C. Morais, A. Scheliga, C. Milito, S. Romano,
M. Land,
R. Schaffel, W. Pulcheri, N. Spector (Federal University of
Rio de Janeiro,
Rio De Janeiro, Brazil) |
COMPARISON OF GENE EXPRESSION
PROFILING BETWEEN MANTLE CELL LYMPHOMA IN LEUKEMIC PHASE AND
NORMAL NAOEVE B-CELLS WITH OLIGONUCLEOTIDE MICROARRAYS
E.G. Rizzatti, A.G. Araújo, M.H. Tavella, A.B. Garcia,
D.A.P. Gallo, R. Proto-
Siqueira, O.K. Okamoto, R.P. Falcão, M.A. Zago (School
of Medicine of
Ribeirão Preto, Ribeirão Preto, Brazil) |
|
|
FISH IS THE BEST
METHOD TO DETECT BCL2/IGH TRANSLOCATION IN FOLLICULAR LYMPHOMA
AT DIAGNOSIS. A COMPARATIVE STUDY WITH CONVENTIONAL CYTOGENETICS,
FISH AND PCR TECHNIQUES USING BIOMED-2 PRIMERS
B. Espinet, B. Bellosillo, E. Gregori, V. Escurriol, M. Salido,
L. Florensa, C. Pedro, C. Besses, S. Woessner, S. Serrano, F.
Sole (Hospital del Mar, Barcelona, Spain) |
ABSENCE OF MALT1 TRANSLOCATIONS
IN MALT LYMPHOMAS OF THE SKIN
B. Espinet, F. Gallardo, R.M. Puijol, T. Estrach, O. Servitje,
S. Serrano, F. Sole (Hospital del Mar, Barcelona, Spain) |
IMPROVED MOLECULAR DIAGNOSIS
OF T(14;18) IN FOLLICULAR LYMPHOMAS: ROUTINE USE OF LONG-DISTANCE
POLYMERASE CHAIN REACTION
S. Vlachova, V. Prochazka, M. Luhovy, M. Divoka, T. Papajik,
M. Jarosova, Z. Pikalova, K. Indrak (University Hospital, Olomouc,
Czech Republic) |
COMBINED ELEVATION OF IL-10,
TNF-ALPHA- AND VEGF PLASMA LEVELS DISCRIMINATE SEVERAL GROUPS
OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WITH A MARKEDLY DIFFERENT
OUTCOME
E. Lech-Maranda, J. Bienvenu, A-L. Debard, S. Tartas, A-S. Michallet,
C. Thieblemont, B. Coiffier, G. Salles (Medical University,
Lodz, Poland) |
INCREASED VASCULARIZATION
PREDICTS FAVORABLE OUTCOME IN FOLLICULAR LYMPHOMA, AND IS NOT
MEDIATED BY VEGF OR RELATED TO PROLIFERATION
A. Koster, H. Tromp, J. Raemaekers, W. Leenders, M. MacKenzie,
H. van Krieken (University Medical Centre Nijmegen, Nijmegen,
The Netherlands) |
ABERRANT SOMATIC HYPERMUTATION
IS INVOLVED IN THE MOLECULAR PATHOGENESIS OF POST-TRANSPLANT
LYMPHOPROLIFERATIVE DISORDERS
C.M. Cerri, D. Rossi, D. Capello, G. Muti, E. Berra, C. Deambrogi,
C. Vendramin, S. Franceschetti, E. Morra, A. Rambaldi, M. Paulli,
G. Gaidano (University of Eastern Piedmont, Novara, Italy) |
STROMA AND INFILTRATING INFLAMMATORY
CELLS BUT NOT THE TUMOR CELLS ARE THE SOURCE OF APRIL/TALL-2
EXPRESSION IN HUMAN MALIGNANT LYMPHOPROLIFERATIVE DISORDERS.
J. Schwaller, P. Mhawech-Fauceglia, C. Cerato, P. Scneider,
J. Tschopp, O. Donze, B. French, B. Huard (Geneva University
Medical School, Geneva, Switzerland) |
CELL CYCLE REGULATORY GENES
EXPRESSION IN DIFFUSE LARGE B-CELL LYMHOMAS
C. Kontsioti, V. Pappa, D. Rontogianni, S. Papageorgiou, E.
Kavada, T. Economopoulos, J. Dervenoulas, E. Papageorgiou, S.
Raptis (Attikon University General Hospital, Athens, Greece) |
|
IF IT IS IN THE
MARROW, IT IS ALSO IN THE BLOOD. CONCORDANCE BETWEEN MARROW
AND BLOOD EXAMINATIONS IN 826 PAIRED SAMPLES FROM 561 LYMPHOMA
PATIENTS
E. Muratori, A. Calleri, C. Rabascio, P. Mancuso, G. Martinelli,
F. Bertolini (European Institute of Oncology, Milan, Italy) |
THE ‘CUTANEOUS VARIANT’
EXHIBITS A FAVORABLE CLINICAL BEHAVIOR WITH RESPECT TO OTHER
CLINICAL PRESENTATIONS OF INTRAVASCULAR LYMPHOMA (IVL): THE
I.E.L.S.G. EXPERIENCE ON 40 CASES
A.J.M. Ferreri, A.J.M. Ferreri, E. Campo, F. Ilariucci, A. Ambrosetti,
J.F. Seymour, R. Willemze, S. Dell’Oro, E. Zucca, M.A.
Piris, P. Iuzzolino, M. Lestani, M. Ungari, N. Frungillo, C.
Doglioni, M. Ponzoni (San Raffaele Scientific Institute, Milan,
Italy) |
IGVH MUTATIONAL STATUS, GENE
USAGE AND IMMUNOPHENOTYPE IN MANTLE CELL LYMPHOMA/LEUKAEMIA.
C. Matthews, M.A. Catherwood, T.C.M. Morris, H.D. Alexander
(Belfast City Hospital, Belfast, Northern Ireland) |
DETECTION OF TCR-GAMMA AND
TCR-DELTA GENE REARRANGEMENT BY PCR IN SKIN AND PERIPHERAL BLOOD
OF PATIENTS WITH EARLY MYCOSIS FUNGOIDES.
G. Goteri, A.R. Scortechini, S. Rupoli, S. Pulini, A. Tassetti,
S. Barulli, A. Filosa, I. Cataldi, G. Brandozzi, D. Brancorsini,
A.M. Offidani, M. Ottaviani, G. Tucci, S. Serresi, R. Capretti,
P. Leoni (Department of Neurosciences, Ancona, Italy) |
ROLE OF CD38 EXPRESSION
IN B-CELL NON-HODGKIN’S LYMPHOMAS IN LEUKEMIC PHASE: CLINICO-BIOLOGICAL
CORRELATIONS
A. Pulsoni, A.R. Guarini, M.S. De Propris, N. Frattarelli, E.
Cavalieri, V. Gianfelici, F. Mancini, F. Cucchi, F.R. Mauro,
R. Foà (University “La Sapienza”, Rome, Italy) |
FRACTIONATED
RADIOIMMUNOTHERAPY WITH DOTACONJUGATED, 90Y-RADIOLABELED, HUMANIZED
ANTI-CD22 MONOCLONAL ANTIBODY (EPRATUZUMAB) APPEARS SAFE AND
EFFICACIOUS ACROSS NHL PATIENT GROUPS
J-F. Chatal, J. Harousseau, F. Griesinger, J. Meller, C. Renner,
C.M. Kirsch, R. Naumann, J. Kropp, M.U. Qidwai, J. Lateiner,
J. Kovacs, C. Ding, W.A. Wegener, I.D. Horak, D.M. Goldenberg
(Institut de Biologie, INSERM, Nantes, France) |
RITUXIMAB IN PATIENTS WITH
HAIRY CELL LEUKEMIA RELAPSING AFTER TREATMENT WITH 2-CHLORODEOXYADENOSINE
(2-CDA)
R.Z. Zenhäusern, A. Von Rohr, K. Rufibach, M. Solenthaler,
S. Meyer-Monard, A. Gratwohl, U. Hess, T. Cerny, M. Bargetzi,
T. Kovacsovic, L. Leoncini, A. Tobler (Inselspital, Bern, Switzerland) |
|
|
HIGH CLINICAL
AND MOLECULAR RESPONSE AFTER A BRIEF CHEMO-IMMUNOTHERAPY FND
+ RITUXIMAB IN ELDERLY PATIENTS WITH DE NOVO ADVANCED STAGE
FOLLICULAR LYMPHOMA (FL)
U. Vitolo, C. Boccomini, M. Ladetto, E. Pogliani, R. Rota Scalabrini,
C. Tarella, C. Castellino, M. Aglietta, M. Astolfi, B. Botto,
A. Carpaneto, P. Corradini, A. Darbesio, A. De Crescenzo, A.
Levis, A.M. Liberati, S. Morandi, L. Orsucci, L. Rigacci, F.
Rossini, A. Tonso, E. Gallo (SC Ematologia 2, Torino, Italy)
|
SUBSEQUENT THERAPY FOR NON-HODGKIN’S
LYMPHOMA IS FEASIBLE AFTER RADIOIMMUNOTHERAPY WITH YTTRIUM-90
IBRITUMOMAB TIUXETAN (ZEVALIN(R))
R.S. Schilder, S.M. Ansell, P.C. Pieslor, L.I. Gordon, C. Emmanouilides,
M.S. Czuczman, H. Wang, T.E. Witzig, M.W. Saville, A. Molina
(Fox Chase Cancer Center, Philadelphia, USA) |
A PHASE I TRIAL OF TWO SEQUENTIAL
DOSES OF ZEVALIN RADIOIMMUNOTHERAPY FOR RELAPSED LOW-GRADE B-CELL
NON-HODGKIN’S LYMPHOMA
G.W. Wiseman, T.E. Witzig (Mayo Clinic, Rochester, USA) |
RITUXIMAB PLUS CLADRIBINE
IN HEAVILY PRETREATED LOWGRADE LYMPHOMA
T. Robak, P. Smolewski, H. Urbanska-Rys, J. Gora-Tybor, J.Z.
Blonski, M. Kasznicki (Medical University of Lodz, Lodz, Poland)
|
COMBINATION OF THE ANTI-CD20
ANTIBODY RITUXIMAB WITH SEQUENTIAL HIGH-DOSE CHEMOTHERAPY FOLLOWED
BY AUTOLOGOUS STEM CELL SUPPORT IN RELAPSED AND REFRACTORY AGGRESSIVE
NON-HODGKIN’S LYMPHOMA
M. Sieniawski, J.O. Staak, H. Scheuss, J.P. Glossmann, V. Diehl,
A. Engert, A. Josting (University Hospital Cologne, Cologne,
Germany) |
EARLIER YTTRIUM-90 IBRITUMOMAB
TIUXETAN (ZEVALIN(R)) TREATMENT IN PATIENTS WITH PREVIOUSLY-TREATED
B-CELL NON-HODGKIN’S LYMPHOMA: HIGHER RESPONSE RATES AND
LONGER DURATIONS OF RESPONSE
C. Emmanouilides, J.L. Murray, K. Vo, T.E. Witzig, M. Darif,
R.J. Schilder, I. Flinn, L.I. Gordon, G. Wiseman, P. Multani,
A. Molina (UCLA, Los Angeles, USA) |
DELAYED-ONSET PERIPHERAL
BLOOD CYTOPENIA AFTER RITUXIMAB. FREQUENCY AND RISK FACTOR ASSESSMENT
IN A CONSECUTIVE SERIES OF 77 TREATMENTS
C. Cattaneo, P. Spedini, G. Ruggeri, A. Tucci, A. Re, E. Borlenghi,
E. Damiani, G. Pelizzari, F. Facchetti, G. Rossi (Spedali Civili,
Brescia, Italy) |
COMBINATION OF EPRATUZUMAB
PLUS RITUXIMAB IN RELAPSED/REFRACTORY INDOLENT AND AGGRESSIVE
NHL: MULTI-CENTER, PHASE-II UPDATE
J. Strauss, J. Strauss, A. Lister, F. Morschauser, M. Gramatzki,
P. Solal-Celigny, P.L. Zinzani, A. Engert, B. Coiffier, D.Hoelzer,
W.A. Wegener, J. Kovacs, M.U. Qidway, C. Ding, I.D. Horak, D.M.
Goldenberg (St. Bartholomew’s Hospital, London, United
Kingdom) |
|
ANALYSIS OF LONG-TERM
RESPONDERS: DURABLE REMISSIONS WITH YTTRIUM-90 IBRITUMOMAB TIUXETAN
(ZEVALIN(R)) RADIOIMMUNOTHERAPY IN PATIENTS WITH RELAPSED OR
REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA
C. Emmanouilides, T.E. Witzig, A. Molina, L.I. Gordon, R.J.
Schilder, I. Flinn, M. Czuczman, H. Wang, C. Theuer, G. Wiseman
(UCLA, Los Angeles, USA) |
RITUXIMAB, GEMCITABINE AND
OXALIPLATIN (R-GEMOX): A PROMISING REGIMEN FOR REFRACTORY/RELAPSED
B-CELL LYMPHOMA
T. El Gnaoui, B. Joly, J. Dupuis, K. Belhadj, A. Rahmouni, C.
Copie-Bergman, A. Allain, I. Tabah-Fisch, F. Reyes, C. Haioun
(Henri Mondor, Créteil, France) |
CNOP VS. CNOP-RITUXIMAB VS.
RITUXIMAB ALONE AS FIRST LINE THERAPY FOR INDOLENT NON-HODGKIN
LYMPHOMA (INHL): PRELIMINARY DISEASE-FREE/OVERALL SURVIVAL ANALYSIS
S. Baltazar, G. Tripp, E. Baez, S. Rivas, L. Solís, G.
Ignacio, J. Duque, O. Garcés, B. Rubio, J.L. Delgado,
P. Rodriguez, H. Castillo, G. Cervantes, B. Batista, J.O. Talavera,
M.E.E. Rubio-Borja (IMSS # 25, Monterrey N.L., Apodaca, Nvo
Leon, Mexico) |
DELAYED SEVERE NEUTROPENIA
AFTER RITUXIMAB THERAPY IN 12 OUT OF 282 PATIENTS WITH NON HODGKIN’S
LYMPHOMA TREATED IN A SINGLE INSTITUTION. A RARE ADVERSE EVENT
OF UNKNOWN MECHANISM
K. Belhadj, K. Doghmi, K. Belhadj, T. El Gnaoui, B. Joly, K.
Lee, A. Plonquet, H. Jouault, C. André, F. Reyes, C.
Haioun (Henri Mondor, Créteil, France) |
SOCS1 AND SHP1
HYPERMETHYLATION IN MULTIPLE MYELOMA: IMPLICATIONS FOR EPIGENETIC
ACTIVATION OF THE JAK/STAT PATHWAY
C.S. Chim, T.K. Fung, W.C. Cheung, R. Liang, Y.L. Kwong (Queen
Mary Hospital, Hong Kong, Hongkong) |
EXPRESSION OF ADHESION MOLECULE
CD58 (LFA-3) ON CD138HIGH AND CD138LOW CELLS IN MULTIPLE MYELOMA.
R. Poglod, J. Kopec-Szlezak, M. Kraj, U. Sokolowska, B. Kruk
(Institute of Hematology and Blood Trans, Warsaw, Poland) |
EXPRESSION OF VASCULAR ENDOTHELIAL
GROWTH FACTOR (VEGF) AND CD31 IN HUMAN MYELOMA CELLS. POTENTIAL
RELATION TO DISEASE PROGRESSION AND TREATMENT RESPONSE
S. Lifshits, T. Yermiahu, M. Kafka, O. Shpilberg, D. Benharroch,
G. Shubinsky (Soroka University Medical Center, Beer-Sheva,
Israel) |
A ROLE FOR RHAMM IN MITOTIC
INTEGRITY AND MYELOMAGENESIS
A. Maxwell, T. Reiman, J.J. Keats, A.R. Belch, L.M. Pilarski
(Cross Cancer Institute, Edmonton, Canada) |
|
|
ASSOCIATION OF
CYTOKINE GENES POLYMORPHISMS WITH MULTIPLE MYELOMA
E. Yakupova, D.Kh. Kalimullina, B.A. Bakirov, T.V. Victorova
(Institute of biochemistry and genetics, Ufa, Russian Federation) |
MULTIPROBE INTERPHASE CYTOGENETICS
DEFINES TWO SUBGROUPS OF MULTIPLE MYELOMA
J. Bila, F.W. Cremer, I. Buck, M. Kartal, D. Hose, A. Mˆbus,
M. Brough, F. Bellos, M. Moos, H. Goldschmidt, A. Jauch (University
of Heidelberg, Heidelberg, Germany) |
PRE-TRANSPLANT VEGF LEVELS
IN MULTIPLE MYELOMA ARE PREDICTIVE FOR PROGRESSION FREE SURVIVAL.
M.C. Politou, E. Terpos, D. Crawley, R. Szydlo, S. Avery, E.
Olavarria, E. Kanfer, J.M. Goldman, J.F. Apperley, A. Rahemtulla
(Imperial College Faculty of Medicine, London, United Kingdom) |
HIGH INCIDENCE OF MONOCLONAL
B-CELL DISEASE (MCBD) IN SIBLINGS (SIBS) OF PATIENTS (PTS) WITH
MULTIPLE MYELOMA (MM)
B. Roth, D. Behringer, J. Finke, M. Engelhardt (University Hospital
Freiburg, Freiburg, Germany) |
VASCULAR ENDOTHELIAL GROWTH
FACTOR (VEGF) AND ITS SOLUBLE RECEPTORS VEGFR-1 AND VEGFR-2
IN THE SERUM OF PATIENTS WITH MULTIPLE MYELOMA
H.R. Urbanska-Rys, A. Wierzbowska, A. Krawczynska, T. Robak
(Copernicus Memorial Hospital, Lodz, Poland) |
SERUM LEVELS OF MIP-1-ALPHA-
ARE USEFUL FOR STUDY OF BONE DISEASE IN MULTIPLE MYELOMA (MM)
AND DIFFERENTIATION FROM MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE
(MGUS) AND BENIGN OSTEOPOROSIS (BO)
J. Hernandez, R.M. Fisac, C. Olivier, J.A. Queizan, B. Suquia,
J. Garcia-Frade, J.A. Portero, R. Lopez, R. Cuello, J.F. San
Miguel (Hospital General de Segovia, Segovia, Spain) |
T CELLS SUPPORT OSTEOCLASTOGENESIS
IN AN IN VITRO MODEL DERIVED FROM HUMAN MULTIPLE MYELOMA BONE
DISEASE
S. Colucci, G. Brunetti, R. Rizzi, G. Mori, G. Colainanni, A.
Liso, S. Capalbo, V. Liso, A. Zallone, M. Grano (Policlinico
di Bari, Bari, Italy) |
PRENYLATION INHIBITORS ALTER
MULTIPLE MYELOMA CELL BIOLOGY
M.A. Morgan, T. Sebil, A. Ganser, C.W.M. Reuter (Hannover Medical
School, Hannover, Germany) |
THE ACTIVATION OF THE PI3K-AKT
PATHWAY IS NOT SUFFICIENT TO PROVIDE LONG TERM SURVIVAL OF HUMAN
MALIGNANT PLASMA CELLS
A. Guenther, F. Bakker, R. Burger, M. Gramatzki (University
of Erlangen, Erlangen, Germany) |
|
RELATIONSHIP
BETWEEN POLYMORPHISMS OF METHYLEN TETRAHYDROFOLATE REDUCTASE
(MTHFR) AND SUSCEPTIBILITY TO MULTIPLE MYELOMA
P. Chiusolo, G. Reddiconto, A. Fiorini, G. Farina, L. Laurenti,
R. Putzulu, M. Palladino, S. Bellesi, F. Sorà, E. Rossi,
M. Tarnani, A. Di Mario, V. De Stefano, G. Leone, S. Sica (Catholic
University, Rome, Italy) |
SERUM FREE LIGHT CHAINS ARE
A SENSITIVE MARKER OF SEROLOGICAL REMISSION IN MULTIPLE MYELOMA
PATIENTS
S.D. Reid, M.T. Drayson, G.P. Mead, B. Augustson, S. Roberts,
A.R. Bradwell (The Binding Site Ltd, Birmingham, United Kingdom)
|
GENE EXPRESSION PROFILING
OF PLASMA CELL DYSCRASIAS REVEALS MULTIPLE MYELOMA MOLECULAR
HETEROGENEITY
M. Mattioli, L. Agnelli, S. Fabris, L. Baldini, F. Morabito,
S. Bicciato, D. Verdelli, D. Intini, L. Nobili, V. Callea, C.
Stelitano, A.T. Maiolo, F. Bonino, L. Lombardi, A. Neri (Ospedale
Maggiore IRCCS Milano,
Milano, Italy) |
INCREASED RISK FOR MULTIPLE
MYELOMA IN INDIVIDUALS WITH THE HOMOZYGOUS 66GG POLYMORPHISM
OF THE METHIONINE SYNTASE REDUCTASE (MTRR) GENE
M.C. Ozelo, C.S.P. Lima, M.M. Ortega, R.C. Araujo, C.A. de Souza,
I. Lorand-Metze, J.M. Annichino-Bizzacchi, F.F. Costa (State
University of Campinas, Campinas, Brazil) |
OPG AND SRANKL IN SERUM OF
UNTREATED MULTIPLE MYELOMA (MM) PATIENTS
M-C. Kyrtsonis, T.P. Vassilakopoulos, A. Papadogiannis, T. Tzenou,
M.N. Dimopoulou, M.P. Siakantaris, S.I. Kokoris, E.M. Dimitriadou,
E.M. Dimitriadou, K. Anargyrou, G.A. Pangalis (University of
Athens, Athens, Greece) |
SERUM SOLUBLE SYNDECAN-1
(S-SYND-1), INSULIN LIKE GROWTH FACTOR (IGF-1) AND MACROPHAGE
INFLAMMATORY PROTEIN-1 ALPHA (MIP-1A) IN UNTREATED MULTIPLE
MYELOMA PATIENTS. RELATIONSHIP WITH PROGNOSIS
M-C. Kyrtsonis, T.P. Vassilakopoulos, A. Papadogiannis, T. Tzenou,
M.N. Dimopoulou, M.P. Siakantaris, S.I. Kokoris, E.M. Dimitriadou,
K. Anargyrou, N.A. Vyniou, P. Korkolopoulou, G.A. Pangalis (University
of Athens, Athens, Greece) |
REAL-TIME QUANTITATIVE
PCR DETECTION OF WT1 GENE TRANSCRIPTS IN CHILDREN WITH ACUTE
LYMPHOBLASTIC LEUKEMIA
J.S. Chen, T.Y. Chen, Ch.Ch. Hsiao, J.M. Sheen, C.N. Cheng (National
Cheng Kung University Hospital, Tainan, Taiwan) |
|
|
ANALYSIS OF BONE
MARROW LYMPHOPOIESIS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
DURING AND AFTER THE CHEMOTHERAPY
G. Shubinsky, E. Israel, S. Atamna, H. Chermoshnuk, I. Dulman,
T. Yermiahu, O. Shpilberg, I. Levi, J. Kapelushnik (Soroka University
Medical Center, Beer-Sheva, Israel) |
SYNERGISTIC CYTOTOXIC EFFECT
OF RAPAMYCIN IN COMBINATION WITH PURINE NUCLEOSIDE ANALOGUES
ON PRE-B ACUTE LYMPHOBLASTIC LEUKEMIA CELLS
P. Smolewski, D. Wierzbicka, S. Piersanti, A. Traverso, B. Cebula,
L. Teodori, T. Robak (Medical University of Lodz, Lodz, Poland)
|
VARIATIONS IN THE RECOMBINATION
ACTIVATING GENES (RAG1/2) IN RELATION TO SUSCEPTIBILITY TO CHILDHOOD
T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
G.M. Taylor, H.P. O’Brien, J.M. Birch, O.B. Eden (University
of Manchester, Manchester, United Kingdom) |
MEK INHIBITOR IN PRIMARY
ADULT ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: OPPOSITE REGULATION
OF EXTRACELLULAR SIGNAL-REGULATED KINASE-1/2 (ERK) AND P21CIP-1/WAF1
C. Gregorj, M.T. Petrucci, M.C. Scerpa, F. De Cave, M.R. Ricciardi,
C.M. Precupanu, A. Vitale, G. Cimino, M. Mancini, M. Vignetti,
M. Milella, M. Andreeff, F. Mandelli, R. Foà, A. Tafuri
(Institute of Hematology, Rome, Italy) |
ZAP-70 IS EXPRESSED IN NORMAL
B-CELLS OF IMMATURE PHENOTYPE AND IN SOME B ACUTE LYMPHOBLASTIC
LEUKEMIAS
M. Crespo, N. Villamor, F. Bosch, E. Giné, E. Campo,
E. Montserrat (Hospital Clinic, Barcelona, Spain) |
HISTONE DEACETYLASE INHIBITORS
ARE ABLE TO CHANGE LEUKAEMIA-SPECIFIC PHENOTYPE OF TEL/AML1-POSITIVE
LEUKAEMIC CELLS
J. Madzo, J. Starkova, M. Vaskova, T. Kalina, J. Trka (CLIP,
Charles University, Prague, Czech Republic) |
SHP-2 AND RAS FUNCTION IN INFANT ALL
S. Martinelli, G. Cazzaniga, L. Corral, A. Leszl, M.G. Dell’Oro,
C. Beretta, M. Spinelli, G. Fazio, B. Scicchitano, G. Basso,
G. De Rossi, M. Tartaglia, A. Biondi (Istituto Superiore di
Sanità, Roma, Italy) |
EXPRESSION OF THE PRE-T CELL
RECEPTOR ALPHA CHAIN IN ACUTE LYMPHOBLASTIC LEUKEMIA CELL LINES
AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET
P. Ivanyi, W. Piao, U. Krug, J. Lauber, K. Steube, A. Ganser,
A. Franzke (Hannover Medical School, Hannover, Germany) |
UPREGULATION OF ASPARAGINE
SYNTHETASE FAILS TO AVERT CELL CYCLE ARREST INDUCED BY L-ASPARAGINASE
IN TEL/AML1-POSITIVE LEUKEAMIC CELLS
J. Starkova, O. Krejci, B. Otova, J. Madzo, O. Hrusak, J. Stary,
J. Trka (Childhood Leukaemia Investigation Prague, Prague, Czech
Republic) |
|
INCIDENCE AND
SIGNIFCIANCE OF 12P13/ETV6 DELETION IN 269 ADULT ACUTE LYMPHOBLASTIC
LEUKEMIA ENROLLED IN THE ALL 0496 AND 2000 GIMEMA TRIAL
C.A. Cuneo, P. Agostini, A. Bardi, E. Tammiso, M. Mancini, M.
Nanni, A. Vitale, L. Melillo, G. Perla, A. Santoro, F. Di Raimondo,
F. Ronco, C. Mecucci, R. Foà, G. Castoldi, I. Attolico
(University of Ferrara, Ferrara, Italy) |
MYELOID ANTIGEN EXPRESSION
IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT ON PROGNOSIS
A. Vitale, A. Guarini, C. Ariola, F. Paoloni, M. Vignetti, F.
Mandelli, R. Foà (University “La Sapienza”,
Rome, Italy)
|
PH CHROMOSOME-POSITIVE
CML PATIENT WITH SUPPURATIVE PERIODONTITIS DURING TREATMENT
WITH IMATINIB (STI571)
M.G. Mele, A. Tartarone, G. Romano, M.L. Vigliotti, R. Matera,
C. Musto, A.M. Capobianco, M. Coccaro, N. Di Renzo (Regional
Hospital, Rionero In Vulture, Italy) |
CD38 EXPRESSION AND NF-KB
ACTIVITY IN B-CLL: EFFECT OF TGF-BETA MODULATION
W. Barcellini, F.G. Imperiali, A. Zaninoni, E. Fermo, A. Zanella
(IRCCS Ospedale Maggiore Policlinico, Milan, Italy) |
VASCULAR ENDOTHELIAL GROWTH
FACTOR IN PATIENTS WITH B- CHRONIC LYMPHOCYTIC LEUKEMIA. ASSOCIATION
WITH THE STAGE AND OTHER PROGNOSTIC MARKERS OF THE DISEASE
E. Kalagiakou, C. Belessi, E. Samaridis, K. Vallianatou, E.
Manioudaki, G. Erotokritou, M. Ioannidou, E. Vigla, S. Kathrepti,
M. Papaefstratiou, G. Kapari, A. Parasi, N. Laoutaris (Hematology
Dept General hospital Nikea, Athens, Greece) |
IDENTIFICATION OF NOVEL MARKER
GENES FOR B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA
S. Grund, B. Olsson, M. Jernas, S. Jacobsson, B. Swolin, L.
Carlsson, H. Wadenvik (Sahlgrenska University Hospital, Göteborg,
Sweden) |
DETECTION OF ZAP-70 BY FLOW
CYTOMETRY USING THE HIGHLY FLUORESCENT ALEXA FLUOR DYE IN CELLS
FROM PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
N.I. Folarin, R.J. Baker, V. Duke, B.C. Yogashangary, C. Vadikolia,
M.W. Lowdell, R.G. Wickremasinghe, A.V. Hoffbrand, A. Nathwani,
A.E. Virchis, A.B. Mehta, L. Foroni, K. Ganeshaguru (Royal Free
& UC Medical School, London, United Kingdom) |
A NOVEL FLOW CYTOMETRY ANALYSIS
METHOD FOR THE QUANTITATION OF ZAP-70 EXPRESSION IN B-CLL CELLS
S. Kay, M. Pick, Y. Herishanu, O. Rogowsky, S. Baron, E. Naparstek,
A. Polliack, V. Deutsch (Tel Aviv Sourasky Medical Center, Tel
Aviv, Israel) |
|
|
INTEGRITY OF
THE DNA SOMATIC HYPERMUTATION (SHM) MACHINERY IN CHRONIC LYMPHOCYTIC
LEUKEMIA (CLL) CELLS
G. Giné, M. Crespo, F. Bosch, N. Villamor, E. Montserrat
(Hospital Clinic of Barcelona, Barcelona, Spain) |
CCR7 RECEPTOR EXPRESSION
IS GREATER IN ZAP70 POSITIVE CLL-B CELLS AND IS ASSOCIATED WITH
GREATER RESPONSIVENESS TO CCLS 19 AND 21.
S.J. Richardson, J.A. Copplestone, A.G. Prentice (Derriford
Hospital, Plymouth, United Kingdom) |
VH GENE USAGE AND CHARACTERISITICS
DIFFERS IN GERMLINE AND MUTATED B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
TO REVEAL TWO DIESEASE GROUPS
V.M. Duke, B.C. Yogashangary, D. Gandini, P.D. Sherrington,
K. Lin, K. Ganeshaguru, A. Nathwani, A.E. Virchis, A.B. Mehta,
A.V. Hoffbrand, L. Foroni (Royal Free & University College
Hospital, London, United Kingdom) |
BIOMED-2 STANDARDISED PRIMERS
AND PROTOCOL FOR ROUTINE ANALYSIS OF IGVH MUTATIONAL STATUS
OBVIATE THE NEED FOR SURROGATE MARKERS IN B-CLL
C. Matthews, M.A. Catherwood, T.C.M. Morris, H.D. Alexander
(Belfast City Hospital, Belfast, Northern Ireland) |
ZAP-70 OVEREXPRESSION IN
T-CELLS OF B-CLL PATIENTS CORRELATES WITH INCREASED LEVELS IN
B-CLL CELLS
Y. Herishanu, S. Kay, M. Pick, O. Rogowsky, E. Naparstek, V.
Deutsch, A. Polliack (Tel Aviv Sourasky Medical Center, Tel-Aviv,
Israel) |
ZAP-70 EXPRESSION IN CHRONIC
LYMPHOCYTIC LEUKEMIA: FLOW CYTOMETRY, IMMUNOCYTOCHEMISTRY AND
WESTERN BLOT ANALYSIS, AND CORRELATION WITH THE IGVH MUTATIONAL
STATUS
A. Guarini, M.S. De Propris, S. Intoppa, S. Masi, M.L. Milani,
C. Ariola, F.R. Mauro, M. Gentile, E. Ghia, R. Foà (University
“La Sapienza”, Rome, Italy) |
ZAP-70 EXPRESSION IN B CHRONIC
LYMPHOCYTIC LEUKAEMIA (B-CLL): MULTIPARAMETER FLOW CYTOMETRY
OR IMMUNOCYTOCHEMISTRY?
D. Dubois, M. Truchan-Graczyk, A. Godon, A. Tanguy-Schmidt,
M.C. Rousselet-Chapeau, N. Ifrah, M. Zandecki, F. Genevieve
(CHU of Angers, Angers, France) |
FLUDARABINE AS
INDUCTION THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A SYSTEMIC
REVIEW AND META-ANALYSIS.
C.L. Tan, Y.C. Linn, Q. Zhu, M. Samuel, E. Chan (Singapore General
Hospital, Singapore, Singapore) |
|
ALEMTUZUMAB
(CAMPATH(R), MABCAMPATH(R)) CONSOLIDATION AFTER FLUDARABINE
PHOSPHATE AND CYCLOPHOSPHAMIDE SECOND-LINE CHEMOTHERAPY FOR
PROGRESSIVE CHRONIC LYMPHOCYTIC LEUKEMIA
L. Orsucci, P. Francia di Celle, A. Stacchini, L. Bergui, C.
Boccomini,
B. Botto, A. Chiappella, L. Godio, P. Pregno, E. Gallo, U. Vitolo
(ASO S. Giovanni Battista, Turin, Italy) |
CANNABINOIDS AS POTENTIAL
ANTILEUKEMIC AGENTS
M. Damri, O. Shpilberg, I. Nathan (Soroka University Medical
Center,
Beer Sheva, Israel) |
IMMUNOTHERAPY OF B-CELL CHRONIC
LYMPHOCYTIC LEUKEMIA WITH AUTOLOGOUS IRRADIATED LEUCAEMIC CELLS
AND BCG
I. Hus, J. Kawiak, J. Rolinski, J. Tabarkiewicz, J. Tabarkiewicz,
K. Wojas, A. Kosek, E. Wasik-Szczepanek, A. Dmoszynska (Medical
University Lublin, Lublin, Poland) |
INTERIM SAFETY SUMMARY OF
ALEMTUZUMAB (CAMPATH(R), MABCAMPATH(R)) VS CHLORAMBUCIL AS FRONT-LINE
THERAPY FOR PATIENTS WITH PROGRESSIVE B-CELL CHRONIC LYMPHOCYTIC
LEUKEMIA
J. Mayer, T. Robak, A. Skotnicki, B. Jaksic, V. Vukovic, S.
Weitman (University Hospital Brno, Brno, Czech Republic) |
PENTOSTATIN AND RITUXIMAB
COMBINATION FOR TREATMENT OF RELAPSED/REFRACTORY HAIRY CELL
LEUKAEMIA - A REPORT OF 3 CASES
N. Osuji, I. Del Giudice, N. Parry-Jones, E. Matutes, C. Dearden,
D. Catovsky (Royal Marsden/Institute Cancer Research, London,
United Kingdom) |
LOW DOSE ORAL FLUDARABINE
PLUS CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE
DISORDERS
A. Fabbri, M. Lenoci, A. Gozzetti, D. Raspadori, G. Marotta,
F. Forconi, F. Lauria (Unit of Hematology/University of Siena,
Siena, Italy) |
ORAL GANCICLOVIR AS PRE-EMPTIVE
TREATMENT IN PATIENTS WITH CMV REACTIVATION DURING ALEMTUZUMAB
TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA
L. Laurenti, P. Piccioni, P. Cattani, A. Cingolani, P. Chiusolo,
M. Tarnani, A. Fiorini, G. Reddiconto, S. De Matteis, G. Fadda,
D. Efremov, S. Sica, G. Leone (Policlinico A. Gemelli, Roma,
Italy) |
CAMPATH 10 MG IN PRETREATED
CLL PATIENTS
L. Laurenti, P. Piccioni, M. Tarnani, P. Chiusolo, M.G. Garzia,
G. Zini, G. Farina, C. Rumi, N. Piccirillo, S. Sica, G. Leone
(Policlinico A. Gemelli, Roma, Italy) |
ALEMTUZUMAB AS FIRST-LINE
THERAPY IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL): LONG-TERM
FOLLOW-UP OF CLINICAL EFFECTS, INFECTIOUS COMPLICATIONS, AND
RISK OF RICHTER TRANSFORMATION (RT)
C. Karlsson, S. Norin, J. Lundin, E. Kimby, H. Mellstedt, B.
Sander, A. Porwit-MacDonald, A. Osterborg (Karolinska University
Hospital, Stockholm, Sweden) |
|
|
CYTOTOXIC T CELL
CLONES AGAINST B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS
CAN BE GENERATED FROM HLA-MATCHED SIBLING DONORS: IMPLICATIONS
FOR
ADOPTIVE IMMUNOTHERAPY
M. Hoogendoorn, J. Olde Wolbers, W.M. Smit, M.R. Schaafsma,
R.M.Y. Barge, R. Willemze, J.H.F. Falkenburg (Leiden University
Medical Center, Leiden, The Netherlands) |
TREATMENT OF
NEWLY DIAGNOSED PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA USING
INTRAVENOUS ARSENIC TRIOXIDE
B. George, V. Mathews, P. Balasubramaniam, R. Shaji, A. Srivastava,
M. Chandy (Christian Medical College, Vellore, Tamilnadu, India) |
SECONDARY ACUTE MYELOID LEUKEMIA:
RESULTS OF CONVENTIONAL TREATMENTS. EXPERIENCE OF GIMEMA TRIALS
L. Pagano, A. Pulsoni, M. Vignetti, M.E. Tosti, P. Falucci,
P. Fazi, L. Fianci, A. Levis, A. Bosi, E. Angelucci, P. Coser,
M. Caira, R. Foà, S. Amadori, F. Mandelli, G. Leone (Università
Cattolica del Sacro Cuore, Rome, Italy) |
RISK-ADAPTED THERAPY OF ADULT
ACUTE MYELOID LEUKAEMIA (AML) INCLUDING MULTIPLE HD-ARA-C CYCLES
WITH LOW-DOSE STEM CELL SUPPORT: EXCELLENT RESULTS FROM A SINGLE
CENTRE
R. Bassan, T. Intermesoli, A. Rambaldi, A. Rossi, E. Oldani,
U. Giussani, P. Bellavita, T. Barbui (Ospedali Riuniti Bergamo,
Bergamo, Italy) |
CYTARABINE BASED REGIMENS
IN ACUTE MYELOID LEUKEMIA: - ASSESSMENT AND COMPARABILITY OF
TREATMENT INTENSITY - USE OF THE CONCENTRATION COEFFICIENT WEIGHTED
AREA UNDER THE CURVE (N-AUC)
J. Braess, M. Fiegl, I. Lorenz, I. Zimmermann, W. Hiddemann
(Klinikum Grosshadern, Munich, Germany) |
RELATIVE SURVIVAL RATES IN
AML PATIENTS IN SWEDEN 1973 - 2000. WHAT IMPACT HAVE NEW TREATMENT
STRATEGIES HAD ON SURVIVAL?
A.E. Rangert, O. Landgren, P. Dickman, S.Y. Kristinsson, M.
Björkholm (Karolinska hospital, Stockholm, Sweden) |
THE TREATMENT COST AND SURVIVAL
OF PATIENTS WITH ACUTE LEUKEMIA -TAIWAN EXPERIENCE
H.C. Hsu, H.H. Chen, H.C. Lu, J.P. Gau, W.K. Chau, C.H. Ho (Taipei-Veterans
General Hospital, Taipei, Taiwan) |
THE COMBINATION OF 2-CDA,
CYTARABINE, MITOXANTRONE AND G-CSF (CLAG-M) AS INDUCTION THERAPY
IN RESISTANT AND RELAPSED ACUTE MYELOID LEUKEMIA - PHASE II
STUDY OF POLISH ADULT LEUKEMIA GROUP (PALG)
A. Wrzesien-Kus, A. Wierzbowska, E. Lech-Maranda, A. Sobczak-Pluta,
J. Holowiecki, S. Kyrcz-Krzemien, S. Grosicki, A. Dmoszynska,
A. Hellmann, K. Kuliczkowski, T. Robak (Medical University,
Lodz, Poland) |
|
EFFICACY OF GEMTUZUMAB
OZOGAMICIN (MYLOTARG) ON ATRA- AND/OR ARSENIC-RESISTANT ACUTE
PROMYELOCYTIC LEUKEMIA (APL) CELLS
A. Takeshita, K. Naito, K. Shinjo, H. Matsui, T. Horii, N. Shirai,
M. Maekawa, K. Ohnishi, T. Naoe, R. Ohno (Hamamatsu University
School of Medicine, Hamamatsu, Japan) |
TREATMENT OF NEW CASES OF
ACUTE PROMYELOCYTIC LEUKAEMIA BY ARSENIC TRIOXIDE
G. Ghavamzadeh, A. Ghavamzadeh, K. Alimoghaddam, R. Hosseini,
N. Aghdami, M. Jahani, Sh. Rostami, H. Ghaffari, Y. Mortazavi,
S.A. Mossavi, B. Bahar, M. Irvani, A. Khodabandeh (Hematology,
Oncology and BMT Research Centre, Tehran, Iran) |
ACUTE LEUKEMIA - CLINICAL
REGISTER (ALERT) IN THE CZECH REPUBLIC 1996-2004
K. Indrak (University Hospital, Olomouc, Czech Republic) |
SAFETY PROFILE OF ZARNESTRA(TM)
(TIPIFARNIB) IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE
MYELOGENOUS LEUKEMIA (AML)
J-L. Harousseau, J. Reiffers, B. Löwenberg, X. Thomas,
F. Huguet, P. Fenaux, R. Stone, J. Lancet, A. Thibault (Hôtel
Dieu, Nantes, France) |
DRUG EXPOSURE IN A PHASE
2 STUDY OF PATIENTS WITH RELAPSED AND REFRACTORY ACUTE MYELOGENOUS
LEUKEMIA (AML) TREATED WITH ZARNESTRA(TM) (TIPIFARNIB)
J-L. Harousseau, J. Reiffers, R. Löwenberg, X. Thomas,
F. Huguet, P. Fenaux, R. Stone, J. Lancet, A. Thibault (Hôtel
Dieu, Nantes, France) |
EFFICACY OF LOW-DOSE ALL-TRANS
RETINOIC ACID IN THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA
S. Cagirgan, M. Pehlivan, M. Hekimgil, M. Tombuloglu (Ege University
Medical School, Izmir, Turkey) |
ATTITUDE TOWARDS REMISSION
INDUCTION (RI) FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA
(AML) AND SURVIVAL. ANALYSIS FROM THE SWEDISH ADULT ACUTE LEUKEMIA
REGISTRY
G. Juliusson, The Swedish Acute Leukemia, R. Billström,
A. Gruber, E. Hellström-Lindberg, M. Höglund, K. Karlsson,
D. Stockelberg, A. Wahlin, M. Åström, C. Arnesson,
E. Holmberg, K. Nordenskjöld, J. Carstensen (Lund University
Hospital, Lund, Sweden) |
EFFICACY AND TOXICITY OF
FLAI VS ICE FOR INDUCTION TREATMENT OF NEWLY DIAGNOSED AML PATIENTS,
YOUNGER THAN 60 YEARS
M. Malagola, G. Martinelli, D. Russo, D. Damiani, A. De Vivo,
A. Candoni, R. Fanin, P.P. Piccaluga, P. Avanzini, G. Gugliotta,
A. Zaccaria, F. Lauria, P. Mazza, M. Gobbi, M. Baccarani (Inst.
of Hematology and Medical Oncology, Bologna, Italy) |
|
|
ATTENUATED FLAIG
REGIMEN IN ELDERLY PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKEMIA
OR MYELODYSPLASIA
C. Ceretto, F. Marmont, E. Audisio, M.A. Ciocca Vasino, A. Busca,
M. Falda, F. Locatelli, S.F. Salvi, L.A. Levis, T.A. Tonso,
G.E. Gallo (Ospedale San Giovanni Battista, Torino, Italy) |
FLUDARABINE, ARABYNOSIL CYTOSINE
AND IDARUBICIN (FLAI), A COMBINATION OF NON MDR-RELATED DRUGS
FOR TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID
LEUKEMIA
M. Malagola, D. Damiani, D. Russo, G. Martinelli, A. Candoni,
A. Michelutti, A. De Vivo, N. Testoni, P. Mazza, M. Gobbi, A.
Zaccaria, F. Lauria, R. Fanin, G. Visani, M. Baccarani (Inst.
of Hematology and Medical Oncology, Bologna, Italy) |
THE ROLE OF ADENOSINE AND
ADENOSINE KINASE IN ACUTE MYELOID LEUKEMIAS WITH METHYLTHIOADENOSINE
PHOSPHORYLASE (MTAP) INACTIVATION
M. Schmid, K. Lehmann, H. Döhner (University of Ulm, Ulm,
Germany) |
5-YEAR SURVIVAL OF ACUTE
MYELOID LEUKEMIA IN ITALY: RESULTS FROM THE EUROCARE-3 STUDY
COMPARED TO GIMEMA MULTICENTRIC PROSPECTIVE TRIALS
P. Fazi, M. Vignetti, A. Verdecchia, F. Paoloni, R. De Angelis,
F. Mandelli (University “La Sapienza”, Roma, Italy) |
CYTOREDUCTION RATE AFTER
HYDROXIUREA PRE-TREATMENT IS AN INDEPENDENT PROGNOSTIC FACTOR
FOR COMPLETE REMISSION IN ADULT AML
M. Vignetti, P. Fazi, M. Sborgia, G. Meloni, A. Tabilio, A.
Chiarenza, V. Liso, E. Angelucci, S. Galimberti, S. Magrin,
A. Camera, L. Melillo, D. De Blasi, F. Ronco, M.C. Petti, F.
Mandelli (University La Sapienza, Roma, Italy) |
TREATMENT OF OLDER AML PATIENTS
WITH LOW-DOSE 5-AZA-2’-DEOXYCYTIDINE (DECITABINE)
M. Lübbert, P.W. Wijermans, B. Rüter, H. Henî
(University of Freiburg Medical Center, Freiburg, Germany) |
ALL-TRANS-RETINOIC ACID (ATRA)
AND VALPROIC ACID (VPA) COMBINATION INDUCE TERMINAL DIFFERENTIATION
IN AML BLASTS
C. Garcia, M.Z. Garcia-Casado, J. Cervera, A. Valencia, J.C.
Pajuelo, L. Senent, M.L. Perez-Sirvent, F. Gomis, A. Sempere,
S. Cantero, M.L. Marty, M.A. Sanz (Hospital Universitario La
Fe, Valencia, Spain) |
ROLE OF CONSOLIDATION THERAPY
IN ADULTS WITH HIGH RISK ACUTE MYELOID LEUKEMIA AGED UP TO 60
YEARS: RESULTS OF A PROSPECTIVE MULTICENTER TRIAL
A. Ganser, J. Krauter, D. Hoelzer, O.G. Ottmann, H. Martin,
M. Lübbert, J. Finke, W. Heit, W. Fiedler, D. Hossfeld,
L. Kanz, G. Schlimok, H. Kirchner, A. Raghavachar, W. Brugger,
G. Heil (Hannover Medical School, Hannover, Germany) |
|
CHARACTERIZATION
OF GENOMIC DELETION OF 5’ ABL AND 3’ BCR IN DER
(9) CHROMOSOME IN CHRONIC MYELOID LEUKEMIA AND RESPONSE TO IMATINIB
MESYLATE
T.K. Saikia, C. Baisane, P.S. Amare-Kadam, K. Satam, N. Kabre,
H. Jain, P.M. Parikh, C.D. Deshmukh (Tata Memorial Hospital,
Mumbai, Bombay, India) |
IMATINIB RESTORES PLASMACYTOID
DENDRITIC CELL FUNCTION IN CHRONIC MYELOID LEUKEMIA PATIENTS
M. Mohty, E. Jourdan, N. Ben Mami, D. Blaise, N. Vey, G. Damaj,
D. Olive, B. Gaugler (Institut-Paoli-Calmettes, Marseille, France)
|
DOSE-ADJUSTMENT OF IMATINIB
BASED ON PLASMA LEVEL MEASUREMENT IN A PATIENT WITH CML
M. Heizmann, N. Widmer, L.A. Decosterd, A. Tobler, E. Oppliger
Leibundgut (University hospital of Basel, Basel, Switzerland)
|
ON THE EXPECTED SURVIVAL
ADVANTAGE OF IMATINIB OVER IFN IN CHRONIC PHASE CML PATIENTS
M. Pfirrmann, J. Hasford (University of Munich, München,
Germany) |
TARGETING OF MCL-1 WITH ANTISENSE
OLIGONUCLEOTIDES COUNTERACTS GROWTH AND VIABILITY OF CML CELLS:
ROLE OF MCL-1 AS A NOVEL BCR/ABL-DEPENDENT TARGET IN CHRONIC
MYELOID LEUKEMIA
K.J. Aichberger, M.M. Mayerhofer, S. Florian, H. Skvara, M.T.
Krauth, C. Akgul, S. Derdak, W.F. Pickl, V. Wacheck, E. Selzer,
B.P. Monia, P. Valent, C. Sillaber (Vienna General Hospital,
Vienna, Austria) |
| ALPHA-1-ACID GLYCOPROTEIN SHOWS INCREASED BINDING
TO IMATINIB AT NEW HIGHER DOSES RECENTLY PROPOSED S.C. Paterson,
K.D. Smith (University of Strathclyde, Glasgow, United Kingdom)
|
CLINICAL SAFETY OF IMATINIB:
A PROSPECTIVE STUDY OF POSSIBLE CLINICAL EFFECTS OF INHIBITION
OF OTHER TYROSINE KINASES IN PATIENTS TREATED FOR CHRONIC-PHASE
CML
J.F. Seymour, A.P. Grigg, M. Hertzberg, J. Matthews, K. Taylor,
N. Guzzo-Pernell, A.K. Mills, M. Copeman, K. Lynch, T.P. Hughes
(Peter MacCallum Institute, Melbourne, Australia) |
SEMI-SYNTHETIC HOMOHARRINGTONINE
FOR PATIENTS WITH CML IN ACCELERATED PHASE RESISTANT TO IMATINIB
J.M. Goldman, J. Kaeda, J.P. Robin, J.F. Apperley, D. Marin
(Imperial College /Hammersmith Hospital, London, United Kingdom) |
AN INTERNATIONAL STUDY TO
STANDARDIZE THE DETECTION OF
BCR-ABL TRANSCRIPTS FROM STABILIZED PERIPHERAL BLOOD PREPARATIONS
BY QUANTITATIVE RT-PCR
M.C. Mueller, G. Saglio, F. Lin, H. Pfeifer, R.D. Press, R.R.
Tubbs, P. Paschka, E. Gottardi, S.G. O’Brien, O.G. Ottmann,
H. Stockinger, M. Ben-Am, L. Wieczorek, K. Merx, U. Schwindel,
R. Hehlmann, A. Hochhaus (III. Medizinische Universitaetsklinik,
Mannheim, Germany) |
|
|
ANALYSIS OF IMATINIB
THERAPY IN 300 PATIENTS WITH BCR-ABL POSITIVE LEUKEMIAS: EVALUATION
OF RESPONSE AND RESISTANCE
T. Lahaye, U. Berger, B. Riehm, S. Kreil, M.C. Müller,
K. Merx, P. Paschka, U. Schwindel, C. Schoch, H. Gschaidmeier,
R. Hehlmann, A. Hochhaus (III. Med. Klinik, Klinikum Mannheim,
Mannheim, Germany) |
THE INFLUENCE OF ARSENIC
TRIOXIDE ON THE CLONOGENIC CAPACITY OF BONE MARROW IN PATIENTS
WITH NEWLY DIAGNOSED CHRONIC PHASE CML.
W.K. Knopinska-Posluszny, W.P. Prejzner, I.T. Topolewska, A.H.
Hellmann (Medical University of Gdansk, Gdansk, Poland) |
IMATINIB TREATMENT NORMALIZES
ABERRANT NEUTROPHIL LEUKOTRIENE C4 SYNTHASE EXPRESSION IN PH+
CML PATIENTS - POTENTIAL INDICATOR OF P210 BCR-ABL SIGNALING
L. Ohm, C. Roos, L. Stenke, S. Widell, J. Lindgren, S. Tornhamre
(Karolinska University Hospital, Stockholm, Sweden) |
CHRONIC MYELOID LEUKEMIA
WITH AN UNCOMMON E8-INT-A2 BCR/ABL FUSION TRANSCRIPT (P200)
AND ATYPICAL HEMATOLOGICAL FEATURES: A CASE REPORT.
D. Diverio, P. Niscola, L. Scaramucci, V. Gomes, N. Giuliani,
F. Palombi, G. Luzi, M. Morucci, R. Foà, M. Montanaro
(University “La Sapienza”, Rome, Italy) |
CYTOGENETIC AND MOLECULAR
MONITORING OF PH+ CHRONIC MYELOID LEUKEMIA (CML) CHILDREN AND
YOUNG ADULTS TREATED WITH IMATINIB MESYLATE (STI571) THERAPY
AT A SINGLE INSTITUTION
F. Giona, M.L. Moleti, M. Fava, C. Alfieri, G. Palumbo, A.M.
Testi, E. Gottardi, M.R. De Cuia, D. Diverio, G. Saglio, R.
Foà (University “La Sapienza”, Rome, Italy)
|
AN FC-GAMMA-RIIA-POLYMORPHIC
SITE AS TARGET FOR ACUTE GRAFT-VERSUS-HOST DISEASE IN PARTIALLY
T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION
H.M. van der Straaten, R. Fijnheer, H.K. Nieuwenhuis, J.G.J.
van de Winkel, L.F. Verdonck (University Medical Centre Utrecht,
Utrecht, The Netherlands) |
A NEW TOOL TO OBJECTIFY DEVELOPMENT
OF FIBROSIS IN CUTANEOUS GRAFT-VERSUS-HOST DISEASE
H.M. van der Straaten, M.R. Canninga-van Dijk, L.F. Verdonck,
D. Castigliego, H.P.E. Borst, J. Aten, R. Fijnheer (University
Medical Centre Utrecht, Utrecht, The Netherlands) |
CYTOMEGALOVIRUS-SPECIFIC
IMMUNE RECOVERY FOLLOWING ALLOGENEIC HLA-IDENTICAL SIBLING TRANSPLANTATION
WITH ANTI-THYMOCYTE GLOBULIN-BASED REDUCED INTENSITY PREPARATIVE
REGIMEN
M. Mohty, A. Mohty, D. Blaise, C. Faucher, K. Bilger, J.A. Gastaut,
D. Olive, B. Gaugler (Institut-Paoli-Calmettes, Marseille, France) |
|
DIFFERENTIATION
OF HUMAN BONE MARROW CELLS INTO CARDIOMYOCYTE-LIKE CELLS: COMPARISON
OF DIFFERENT INDUCTION PROTOCOLS
J.L. Rummens, V. Peeters, M. Hendrikx, U. Mees, P. Steels, F.
Vandenabeele, C. Clijsters (Virga Jesse Hospital, Hasselt, Belgium)
|
DIFFERENTIAL ROLE OF CD97
IN IL-8-INDUCED AND G-CSF-INDUCED STEM CELL MOBILIZATION
M. van Pel, M.J. Kwakkenbos, H. Hagoort, I.J.D. Lindley, R.
Willemze, J. Hamann, W. Fibbe (Leiden University Medical Center,
Leiden, The Netherlands) |
TRANSPLANTATION WITH EX-VIVO
THROMBOPOIETIN-EXPANDED CD34POS CORD BLOOD CELLS ACCELERATES
PLATELET RECONSTITUTION IN NOD/SCID MICE
Y. van Hensbergen, L.F. Schipper, A. Brand, M.C.S. Slot, W.
Fibbe (Sanquin Bloodbank, Leiden, The Netherlands) |
MONITORING OF CHIMERISM AFTER
ALLOGENIC PERIPHERAL BLOOD STEM CELL OR BONE MARROW TRANSPLANTATION
USING MULTIPLEX PCR AMPLIFICATION OF SHORT TANDOM REPEAT MARKER
B. Chahardouli, S.H. Ghaffari, A. Gavamzadeh, K. Alimoghadam,
Y. Mortazavi, M. Jahani, B. Bahar, M. Iravani, S.A. Mosavi (University
of Tehran Medical Science, Tehran, Iran) |
IN VITRO COSTIMULATION SIGNIFICANTLY
IMPROVES IN VIVO POTENTIAL OF CULTURED HUMAN T LYMPHOCYTES IN
HU-PBL-RAG2-/-GAMMAC-/-MICE
R.S. van Rijn, E.R. Simonetti, A. Hagenbeek, M.L. Bonyhadi,
L. van Bloois, S.B. Ebeling (University Medical Center Utrecht,
Utrecht, The Netherlands) |
ADMINISTRATION OF CYCLOPHOSPHAMIDE
SHORTLY BEFORE TOTAL BODY IRRADIATION AND TRANSPLANTATION DECREASES
ENGRAFTMENT OF BOTH ADULT BONE MARROW AND FETAL LIVER HEMATOPOIETIC
STEM CELLS
K-T. Chang, L. Sefc, T. Pelichovska, E. Necas (First Medical
School, Charles University, Prague, Czech Republic) |
RHODAMINE123 DYE-EXCLUDING
CELL SUSPENSIONS DERIVED FROM CULTURES OF HUMAN CD34+ CORD BLOOD
CELLS CONTAIN EARLY HEMATOPOIETIC PROGENITOR CELLS ABLE TO RECONSTITUTE
HEMATOPOIESIS IN VIVO
L. Kindler, V. Vallet, M. von Planta, D. Suva, C. Soulas, B.
Chapuis, M.A. Duchosal (Geneva University Hospital, Geneva,
Switzerland) |
MOLECULAR MONITORING OF MINIMAL
RESIDUAL DISEASE AFTER REDUCED INTENSITY CONDITIONING AND ALLOGENEIC
TRANSPLANTATION IN RELAPSED PATIENTS WITH CHRONIC LYMPHOCYTIC
LEUKEMIA AND LOW-GRADE LYMPHOMAS
L. Farina, M. Carrabba, E. Rizzo, A. Dodero, A. Locasciulli,
A. Olivieri, A. Rambaldi, R. Scimè, A. Santoro, C. Tarella,
M. Bregni, A.M. Gianni, P. Corradini (Istituto Nazionale Tumori,
Milano, Italy) |
|
|
KINETICS OF CHIMERISM
IN DIFFERENT PREPARATIVE CONDITIONING REGIMENS AND GVHD
L. Savino, M.M. Greco, A.M. Carella (Casa Sollievo Della Sofferenza,
San Giovanni Rotondo, Italy) |
ISOLATION AND CHARACTERIZATION
OF LYMPHOCYTES DERIVED FROM INTESTINAL BIOPSIES AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION AND IN GRAFT-VERSUS-HOST DISEASE
K. Rieger, T. Fietz, D. Sommer, W. Knauf, E. Thiel, L. Uharek
(Charite- Campus Benjamin Franklin, Berlin, Germany) |
COMPARISON OF LYMPHOID SUBSETS
IN THE LATE POSTRANSPLANT PERIOD BETWEEN PATIENTS UNDERGOING
ALLOGENEIC STEM CELL TRANSPLANT AND THEIR RESPECTIVE DONORS
USING LYMPHOGRAM(R)
F.M. Sanchez-Guijo, L.I. Sanchez-Abarca, M.D. Caballero, E.M.
Villaron, M. Alberca, N. Lopez-Holgado, J.A. Perez- Simon, M.C.
del Cañizo, A. Orfao, J.F. San Miguel (Hospital Universitario
de Salamanca, Salamanca, Spain) |
CYTOTOXIC ACTIVITIES OF HUMAN
HLA IDENTICAL DONOR DERIVED CYTOKINE INDUCED CELLS (CIK) AGAINST
ACUTE MYELOID BUT NOT LYMPHOID LEUKEMIA BLASTS
A.M. Barbui, G. Borleri, M. MicÚ, A. Salvi, M. Introna,
A. Rambaldi (Ospedali Riuniti di Bergamo, Bergamo, Italy) |
AUTOLOGOUS STEM
CELL TRANSPLANTATION (ASCT) IN 102 PATIENTS WITH AGGRESSIVE
OR FOLLICULAR NON-HODGKIN’S LYMPHOMA BETWEEN 8/84 AND
9/03 - A SINGLE CENTER REPORT
H.K. Kasparu, J. König, H. Hauser, O. Krieger, M. Girschikofsky,
M. Bernhart, D. Lutz (KH Elisabethinen, Linz, Austria) |
RELATION BETWEEN HARVEST
SUCCESS AND OUTCOME AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION IN MULTIPLE MYELOMA
A. Wahlin, M. Eriksson (University Hospital of Umea, Umea, Sweden) |
MYELOMA IS AN INDEPENDANT
RISK FACTOR FOR THE DEVELOPMENT OF CYTOMEGALOVIRUS FOLLOWING
STEM CELL TRANSPLANTATION.
J.A. Ruell (Christie Hospital, Manchester, United Kingdom) |
OPTIMIZATION OF CD34+ CELL
COLLECTION FOR AUTOLOGOUS TRANSPLANTATION USING EVOLUTION OF
PERIPHERAL BLOOD CELL COUNTS AFTER MOBILIZATION CHEMOTHERAPY
I. Lorand-Metze, M.T. Delamain, J.F.C. Marques Jr, A.R.C. Reis,
C.A. De Souza, K. Metze (State University of Campinas, Campinas,
Brazil) |
|
AUTOLOGOUS STEM
CELL RESCUE WITH CRYOPRESERVED PERIPHERAL BLOOD PROGENITORS
(PBSC) USING 5% VERSUS 10% DIMETHYLSULOXIDE (DMSO) IN PATIENTS
WITH HEMATOLOGICAL MALIGNANCES
A. Pivkova, B. Georgievski, L. Cevreska, N. Siljanovski, Z.
Stojanoski, I. Panovska, M. Pavkovic, M. Ivanovski, S. Genadieva-Stavric,
V. Milenkov, R. Dukovski, P.Gerasimovska, G.D. Efremov (Department
of hematology, Clinical Center, Skopje, Macedonia) |
IMMUNOABLATIVE THERAPY WITH
AUTOLOGOUS STEM CELL SUPPORT IN THE TREATMENT OF 27 PATIENTS
WITH POOR RISK MULTIPLE SCLEROSIS
T.K. Kozak, E. Havrdova, J. Pitha, K. Mayerova, E. Gregora,
P. Kobylka, S. Vodvarkova, M. Trneny, J. Fiedler, P. Skopek,
V. Koza, M. Kolar, J. Pachl (University Hospital Kralovske Vinohrady,
Prague, Czech Republic) |
ARA-C BASED CHEMOTHERAPY
AND G-CSF INDUCE HIGH RATE OF PROGENITOR CELL MOBILIZATION IN
ACUTE LEUKAEMIA PATIENTS
F. Ciceri, T. Intermesoli, E. Oldani, G. Rossi, P. Fabris, E.
Pogliani, F. Marmont, R. Sancetta, E. Di Bona, E. Angelucci,
A. Gallamini, G. Lambertenghi-Deliliers, A. Rambaldi, T. Barbui,
R. Bassan (H San Raffaele, Milano, Italy) |
“HIGH RISK”
PATIENTS WITH AGGRESSIVE NON-HODGKIN’S LYMPHOMA SHOULD
BE TRANSPLANTED IN FIRST REMISSION (SINGLE CENTER EXPERIENCE)
L. Cevreska, S. Gendieva-Stavric, B. Georgievski, I. Panovska,
M. Ivanovski, Z. Stojanoski, M. Lozance (Clinical center, Skopje,
Macedonia) |
HIGH INCIDENCE OF NEUTROPENIA
IN PATIENTS TREATED WITH RITUXIMAB AFTER AUTOLOGOUS STEM CELL
TRANSPLANTATION
P. Brasca, R. Cairoli, G. Grillo, A. Tedeschi, P. Marenco, G.
D’Avanzo, E. Morra (Ospedale Niguarda, Milano, Italy) |
THREE YEARS’ FOLLOW-UP
IN A RANDOMIZED, DOUBLE-BLIND COMPARATIVE STUDY OF PARENTERAL
NUTRITIONAL SUPPORT WITH OR WITHOUT GLUTAMINE IN AUTOLOGOUS
STEM CELLS TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES
A. Sykorova, J. Horacek, P. Zak, M. Kmonicek, J. Maly (Charles
University Hospital, Hradec Kralove, Czech Republic) |
PERIPHERAL BLOOD STEM CELL
(PBSC) : COMPARISON OF TWO METHODS OF COUNTING; CD34 BY FLOW
CYTOMETRY (IF) AND HEMATOPOIETIC PROGENITOR CELL (HPC)
COUNT ON SYSMEX(R) XE-2100
M.I. Belkaid, N. Bakiri, A.M. Pequin, J.C. Saly, E. Chirpaz,
T. Henni (CHD Felix Guyon, Saint Denis, Reunion) |
PERIPHERAL BLOOD PROGENITOR
CELLS (PBPCS) ARE EFFECTIVELY MOBILISED BY PEGFILGRASTIM (NEULASTA(R))
L.R. Silverman, E. Johnston, P. Chahinian, J. Mandeli, G. Molineux
(The Mount Sinai Hospital, New York, USA) |
|
|
FEASIBILITY OF
INTERLEUKIN-2 ADMINISTRATION FOLLOWING AUTOLOGOUS PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA (AML)
PATIENTS IN IST COMPLETE REMISSION
S.M. Trisolini, S. Capria, E. Baldacci, M.L. Dessanti, D. Diverio,
A. Guarini, R. Foà, F. Mandelli, G. Meloni (University
“La Sapienza”, Rome, Italy) |
FXIII VAL34LEU
POLYMORPHISM IS ASSOCIATED WITH THROMBIN GENERATION IN HEALTHY
SUBJECTS
R. Lecumberri, R. Montes, M.L. López, J. Hermida, I.
Alberca, E. Rocha (University Clinic of Navarra, Pamplona, Spain)
|
AN ITALIAN PROSPECTIVE REGISTRY
OF CATHETER-RELATED COMPLICATIONS IN PATIENTS WITH HEMATOLOGICAL
MALIGNANCIES (CATHEM)
A. Cortelezzi, A. Cortelezzi, M. Moia, A. Falanga, E.M. Pogliani,
A.M. Nosari, M. Boccadoro, E. Gallo, V. Rizzoli, F. Rodeghiero,
C. Annaloro, B. Oliviero (University of Milan, Milano, Italy) |
ANALYSIS OF PREDISPOSING
FACTORS AND SIX MONTH OUTCOMES OF DVT MANAGEMENT IN 668 PATIENTS
TREATED WITH LMWH (TINZAPARIN) AS OUTPATIENTS
S. Rhodes, S. Bond, E.S. Green (Great Western Hospital, Swindon,
United Kingdom) |
BLEEDING COMPLICATIONS OF
ORAL ANTICOAGULANT THERAPY: A PROSPECTIVE AUDIT
S. Rhodes, E.S. Green, S. Bond, R. James, M. Taylor, P. Rose,
C. Emmas (Great Western Hospital, Swindon, United Kingdom) |
INITIAL OUTPATIENT TREATMENT
OF PULMONARY EMBOLISM WITH FONDAPARINUX (ARIXTRA(R)): THE MATISSE-PE
TRIAL
F. Piovella, Matisse investigators (IRCCS Policlinico San Matteo,
Pavia, Italy) |
FONDAPARINUX IN THE TREATMENT
OF DEEP-VEIN THROMBOSIS AND PULMONARY EMBOLISM
H.R. Buller, Matisse Investigators (Academic Medical Center,
Amsterdam, The Netherlands) |
GIESSEN THROMBOPHILIA STUDY:
MANIFESTATION AGE OF THROMBOEMBOLISM IN THROMBOPHILIA
B. Kemkes-Matthes, K.J. Matthes, H. Kattenborn, H. Pralle (Zentrum
Innere Medizin, Giessen, Germany) |
THROMBOPROPHYLAXIS WITH FONDAPARINUX
IN ACUTELY ILL MEDICAL PATIENTS WITH MODERATE RENAL IMPAIRMENT
A.T. Cohen, Artemis (Guy’s, King’s and St. Thomas’
School of M, London, United Kingdom) |
|
THE MANAGEMENT
OF PATIENTS ON LONG TERM ORAL ANTICOAGULANT TREATMENT (OAT)
UNDERGOING ELECTIVE MAJOR SURGERY: A PROSPECTIVE OBSERVATIONAL
STUDY
F. Baudo, G. Mostarda, M. Molinotti, V. Pengo, D. Poli, E. Tiraferri,
A. Tosetto, E. Morra (Niguarda Hospital, Milan, Italy) |
ANAEROBIC BACTEREMIA
IN NEUTROPENIC PATIENS WITH LEUKEMIA AND LYMPHOMA. OROPHARYNGEAL
MUCOSITIS AND STATUS OF HEMATOLOGIC DISEASE ARE THE MOST IMPORTANT
PREDISPOSING CONDITIONS.
A. Candoni, R. Trevisan, M. Battista, M. Castelli, R. Mestroni,
R. Fanin (University of Udine, Udine, Italy) |
CASPOFUNGIN (CANCIDAS) AS
FIRST LINE TREATMENT FOR 32 PROVEN OR PROBABLE INVASIVE FUNGAL
INFECTIONS IN ONCOHEMATOLOGIC NEUTROPENIC PATIENTS.
A. Candoni, R. Mestroni, T. Michelutti, M. Tiribelli, R. Fanin
(University of Udine, Udine, Italy) |
CRYPTOCOCCOSIS IN PATIENTS
WITH HEMATOLOGICAL MALIGNANCIES. EXPERIENCE OF GIMEMA-INFECTION
L. Pagano, L. Fianchi, C. Caramatti, D. D’Antonio, L.
Melillo, L. Masini, G. Todeschini, C. Girmenia, B. Martino,
S. Cinieri, P. Falcucci, G. Trape, R. Piscitelli, M. Caira,
P. Martino, A.D. Del Favero (Università Cattolica del
Sacro Cuore, Rome, Italy) |
SCREENING FOR ASPERGILLUS
GALACTOMANNAN ANTIGENEMIA: THE ROLE IN A HEMATOLOGY UNIT
A. Sonet (University Hospital of Mont-Godinne, Yvoir, Belgium) |
THROMBOCYTOSIS AND TOXOCARIASIS
: REPORT OF TWO PEDIATRIC CASES
S. Kagialis-Girard, V. Mialou, M. Ffrench, M.P. Pages, Y. Bertrand
(Hôpital Debrousse-Hospices Civils de Lyon, Lyon, France) |
FATAL HEMOPHAGOCYTIC SYNDROME
WITH EVIDENCE OF HHV-8 INFECTION IN THREE IMMUNOCOMPETENT SUBJECTS
A. Re, M.A. Capucci, F. Facchetti, M. Luppi, O. Barozzi, N.
Petrella, E. Borlenghi, M. Ungari, P. Barozzi, G. Rossi (Spedali
Civili di Brescia,
Brescia, Italy)
|
REMISSION OF
REFRACTORY ITP AFTER TREATMENT FOR HELICOBACTER PYLORI INFECTION-
A CASE REPORT
Z. Habibi, A. Mohammadi, M. Ghahramani, F. Saeed, A. Mansouri,
E. Habibi (Emam Hossien Hospital, Zanjan, Iran) |
RITUXIMAB IN
THE TREATMENT OF RELAPSED AND REFRACTORY IMMUNE THROMBOCYTOPENIA
A. Stojanovic, S. Trajkova (Medical Faculty, Skopje, Macedonia) |
|
|
TREATMENT OF
PATIENTS WITH REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA WITH
ANTI- CD20 MONOCLONAL ANTIBODY (RITUXIMAB).
A. Vassou, E. Tzouvara, V. Alymara, A. Chaidos, K. Bourantas
(University of Ioannina Medical School, Ioannina, Greece) |
DANAZOL THERAPY IN CHRONIC
IDIOPATHIC THROMBOCYTOPENIC PURPURA: LONG-TERM RESULTS
E. Andres, J. Zimmer, E. Noel, F. Maloisel (Hôpitaux Universitaires
de Strasbourg, Strasbourg, France) |
TITER OF ANTI-HEPARIN / PF4-ANTIBODIES
AND PLATELET ACTIVATION MARKERS IN HEPARIN INDUCED THROMBOCYTOPENIA
G. Colucci, B. Lämmle, L. Alberio (Inselspital, University
Hospital, Bern, Switzerland) |
DO WE HAVE THE TOOLS TO CURE
REFRACTORY ADULT CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA?
S. Tavera, M. Bonferroni, G. Cavallero, M. Grasso, R. Calvi,
D. Rapezzi, A. Gallamini (S. Croce e Carle, Cuneo, Italy) |
ITP IN PREGNANCY - A DIAGNOSTIC
AND THERAPEUTIC CHALLENGE A.M.
Vladareanu, H. Bumbea, S. Avram, D. Barbu, D. Mut Popescu, A.
Lupu, R. Vladareanu, L. Cobac (Coltea Hospital, Bucharest, Romania)
|
THE IN VITRO
ASSESSMENT OF TNF ACCOMPANYING ABO & RHD INCOMPATIBILITIES
K. Kadkhoda, A.A. Pourfathollah, S.M. Moazzeni (Tarbiat Modares
University, Tehran, Iran) |
METHYLENE BLUE-PHOTOINACTIVATED
PLASMA VERSUS FRESH FROZEN PLASMA AS REPLACEMENT FLUID FOR PLASMA
EXCHANGE IN THROMBOTIC THROMBOCYTOPENIC PURPURA
A. Alvarez-Larrán, J. Del Río, C. Ramírez,
C. Albo, F. Peña, A. Campos, J. Cid, J. Muncunill, J.L.
Sastre, C. Sanz, A. Pereira (Hospital Clínic, Barcelona,
Spain) |
CLINICAL SIGNIFICANCE OF
FC-GAMMA-R IIA AND FC-GAMMA-R IIIA POLYMORPHISMS IN KOREAN PATIENTS
WITH ACUTE AND CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA
H.M. Kim, K.U. Chun, J.Y. Shim, Y. Uh, M.K. Kim, K.C. Lee (Yonsei
Univ. Wonju College of Medicine, Wonju, South-Korea) |
SEVERE CASE OF NEONATAL ALLOIMMUNE
THROMBOCYTOPENIA PROBABLY DUE TO ANTI-HPA-3A
K. Schallmoser, J. Kutschera, S. Macher, U. Posch, T. Wagner,
S. Panzer, G. Lanzer (Medical University of Graz, Graz, Austria)
|
ANALYSIS OF IN VITRO FUNCTION
OF PLATELETS STORED IN PLASMA OR PLATELET ADDITIVE SOLUTION
(PAS III) BY ROTATION THROMBELASTOGRAPHY AND PLATELET AGGREGOMETRY
K. Schallmoser, S. Macher, T. Wagner, G. Lanzer (Medical University
of Graz, Graz, Austria) |
|
HAEMOVIGILANCE:
PROPOSAL FOR A COMPREHENSIVE CLASSIFICATION OF TRANSFUSION-RELATED
EVENTS
M.A. Siegenthaler, Ph. Schneider, D-H. Vu, J-D. Tissot (Service
régional de transfusion sanguine, Lausanne, Switzerland) |
EFFECTIVENESS OF RITUXIMAB
IN THE TREATMENT OF ADULT PATIENTS WITH REFRACTORY AUTOIMMUNE
CYTOPENIAS
N.C. Giannakoulas, E. Arvanitopoulou, S. Kougelou, A. Kouraklis-Symeonidis,
M. Tiniakou, E. Fragopanagou, E. Solomou, V. Lambropoulou, M.
Palasopoulou, A. Symeonidis, P. Matsouka, N.C. Zoumbos (University
Hospital of Patras, Rion, Patras, Greece) |
A STUDY TO DETERMINE THE
REASONS FOR NOT TRANSFUSING CROSSMATCHED BLOOD: AN AREA FOR
IMPROVEMENT
A. Sah, S. MacLennan, L.A. Parapia, S. Brown, A.T. Williams
(Leeds General Infirmary, Leeds, United Kingdom) |
AN OPEN LABEL, MULTI-CENTER
STUDY ON THE EFFICACY AND SAFETY OF ANTI-D IMMUNOGLOBULIN IN
PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
A. Salama, L.M. Aledort, I. Andresen, O. Zenker (University
Clinics Charité, Berlin, Germany) |
IN MULTIPLE MYELOMA,
FISH DOES NOT REVEAL CHROMOSOMAL ABERRATIONS INVOLVING THE DKK1
GENE LOCUS AT CHROMOSOME BAND 10Q11
C. Wendl, H. Döhner, P. Liebisch (University Hospital of
Ulm, Ulm, Germany) |
THE HUMAN TUMOR
PROTEIN D52 (TPD52): A NEW B-CELL/ PLASMA CELL MOLECULE IDENTIFIED
THROUGH A PROTEOMIC APPROACH AND CHARACTERIZED BY A UNIQUE EXPRESSION
PATTERN
E.T. Tiacci, P.L. Orvietani, B. Bigerna, A. Pucciarini, G. Corthals,
A. Liso, R. Pacini, S. Pileri, M. Gambacorta, R. Benedetti,
A . Tabarrini, M.T. Sciurpi, F. Frenguelli, L. Binaglia, J.A.
Byrne, B. Falini (Section of Hematology, Perugia, Italy) |
INCIDENCE AND PROGNOSTIC
IMPACT OF CHROMOSOMAL ABNORMALITIES DETECTED BY INTERPHASE FLUORESCENCE
IN SITU HYBRIDIZATION IN PATIENTS WITH B-CHRONIC LYMPHOCYTIC
LEUKEMIA
L. Sindelarova, K. Michalova, Z. Zemanova, L. Babicka, S. Ransdorfova,
J. Brezinova, S. Pekova, J. Schwarz, J. Karban, E. Cmunt (General
Faculty Hospital, Prague, Czech Republic) |
SINGLE NUCLEOTIDE
POLYMORPHISMS OF THE BCL-6 PROTO-ONCOGENE: CORRELATION TO CLINICAL
FEATURES AND OUTCOME IN FOLLICULAR LYMPHOMAS
F. Jardin, F. Parmentier, P. Ruminy, N. Courel, G. Buchonnet,
A. Stamatoullas, H. Tilly, C. Bastard (Centre Henri Becquerel,
Rouen, France) |
|
|
GENETIC CHANGES
IN LEUKEMIC LYMPHOPROLIFERATION WITH MANTLE CELL HENOTYPE
P. Papajík, M. Jarosova, S. Vlachova, Z. Pikalova, L.
Raida, V. Prochazka, J. Vondrakova, R. Urbanova, K. Indrak (University
Hospital, Olomouc, Czech Republic) |
SPECTRAL KARYOTYPING REFINES
CYTOGENETIC DIAGNOSTICS OF CHROMOSOMAL ABNORMALITIES IN SPLENIC
MARGINAL ZONE B-CELL LYMPHOMA (SMBCZL) AND MANTLE CELL LYMPHOMA
(MCL)
L. Astier, B. Espinet, M. Salido, L. Florensa, S. Serrano, F.
Solé (Hospital del Mar, Barcelona, Spain) |
FUNCTIONAL ANALYSIS OF THE
PAX5/TEL CHIMERIC PROTEIN
G. Fazio, C. Palmi, A. Cassetti, A. Villa, A. Biondi, G. Cazzaniga
(Centro Ricerca Tettamanti, Monza, Italy) |
GENE EXPRESSION PROFILING
OF POST-TRANSPLANTATION LYMPHOMAS
V. Vallet, T. McKee, M. Schapira, I. Stamenkovic, M.A. Duchosal
(CHUV, Lausanne, Switzerland) |
TEL/ARG INDUCES CYTOSKELETAL
ABNORMALITIES IN 293T CELLS
C. Palmi, G. Fazio, A. Cassetti, A. Villa, A. Biondi, G. Cazzaniga
(Centro Ricerca Tettamanti, Monza, Italy)
|
IN MALIGNANT LYMPHOCYTES
EXPRESSION OF DAXX INCREASES APOPTOSIS BY PROMOTING EXTRINSIC
SIGNALING
S. Boehrer, S. Schaaf, M. Bergmann, A. Brieger, D. Nowak, D.
Hoelzer, P.S. Mitrou, E. Weidmann, K.U. Chow (Johan Wolfgang
Goethe University, Frankfurt, Germany) |
G-CSF MOBILIZATION INDUCES
SIGNIFICANT CHANGES IN GENE EXPRESSION PROFILE WHICH ARE UNDETECTED
THREE MONTHS LATER.
C. Castilla, N.C. Gutierrez, I.M. Isidro, E.M. Ocio, M. Delgado,
P. Maiso, M.C. Cañizo, J.M. Hernandez, J.F. San Miguel
(Hospital Clinico de Salamanca, Salamanca, Spain) |
TCR REPERTOIRE AND LYMPHOID
MALIGNANCIES: A FAMILIAL STUDY
S. Bonfigli, C. Fozza, F. Dore, F. Culurgioni, G. Broccia, E.
Angelucci, M. Longinotti (Hematology. University of Sassari,
Sassari, Italy)
|
SYNTHETIC ADENOSINE
RECEPTOR AGONISTS MODULATE MURINE HAEMATOPOIESIS: A STUDY EMPLOYING
THE CYTOTOXIC ACTION OF 5-FLUOROURACIL
M. Hofer, M. Pospisil, A. Vacek, V. Znojil, I. Pipalova (Inst
Biophys, Acad Sci Czech Rep, Brno, Czech Republic) |
|
REGULATORY ROLE
OF ADENOSINE SIGNALLING IN HAEMATOPOIESIS: MOBILIZATION AND
IN VITRO STUDIES
L. Weiterová, M. Hofer, M. Pospí~sil, V. Znojil
(Institute of Biophysics, Brno, Czech Republic) |
EFFECT OF TGF-fl, INHIBITORS
OF MITOGEN-ACTIVATED PROTEIN KINASES AND PROTEASOME INHIBITOR
ON TGF-fl RECEPTORS MRNAS, SMAD MRNAS AND TARGET PROTEIN P21CIP1/WAF1
MRNA LEVELS IN CTV-1 LEUKAEMIA CELL LINE
O. Fuchs, D. Provaznikova, G. Peslova, V. Ullmannova (Institute
of Haematology and Blood Trans, Prague, Czech Republic) |
TUMOR NECROSIS FACTOR, LYMPHOTOXINI-ALPHA
AND INTERLEUKIN 6 GENETIC POLYMORPHISMS AND RISK OF DEVELOPMENT
HEMATOLOGICAL MALIGNANCES
E. Yakupova, T.N. Krasavtceva, O.A. Malyevsky, T.V. Victorova
(Institute of biochemistry and genetics, Ufa, Russian Federation) |
EFFECT OF TUMOR NECROSIS
FACTOR ON ADHESIVENESS OF HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS
(HUVECS) IN NON-HODGKIN’S LYMPHOMAS AND GASTRIC CANCER
V.L. Matlan, V.A. Barilka, S.V. Novak, N.A. Volodko, I.G. Gipp,
V.A. Piddubniak, B.T. Bilynsky, V.E. Loginsky (Institute of
Blood Pathology, Lviv, Ukraine) |
CLINICAL RELEVANCE OF VASCULAR
ENDOTHELIAL GROWTH FACTOR (SVEGF) LEVELS IN CHILDREN WITH ACUTE
LEUKEMIAS AND MALIGNANT LYMPHOMAS
G. Yavuz, H. Ugur, G. Yavuz, N. Tacyildiz, E. Unal, E. Babacan,
A. Ikinciogullari, Y. Egin, S. Erekul, G. Kaygusuz, I. Kuzu,
S. Gozdasoglu, S. Cin (Ankara University, School of Medicine,
Ankara, Turkey) |
REQUIREMENT OF ERYTHROID
CELL STIMULATING FACTOR DURING ENHANCED ERYTHROPOIESIS
K.B. Udupa (Univ. Ark. Med. Sci. & V. A. Med. Center, Little
Rock, AR, USA) |
INCREASED SERUM LEVEL OF
MACROPHAGE INFLAMMATORY PROTEIN - 1 (MIP-ALPHA-/CCL3) BUT NOT
RANTES/CCL5 IN PATIENTS WITH B-CELL LYMPHOPROLIFERATIVE DISORDERS
(MULTIPLE MYELOMA AND NON-HODGKIN’S) LYMPHOMA)
G. Mazur, T. Wrobel, L. Usnarska-Zubkiewicz, K. Kuliczkowski
(Wroclaw Medical University, Wroclaw, Poland) |
A META-ANALYSIS OF FILGRASTIM
DOSING DURATION FOR CHEMOTHERAPY-INDUCED NEUTROPENIA IN NONMYELOID
MALIGNANCIES
M. Green, R. Baynes (Royal Melbourne and Western Hospitals,
Victoria, Australia) |
ACUTE MYELOGENOUS LEUKEMIA
(AML) FOLLOWED BY METASTATIC GALL BLADDER CANCER: EFFICACY AND
SAFETY OF INTERLEUKIN-2
A. Chierichini, V. Bongarzoni, F. Monardo, C. Napolitano, P.
Iacovino, M. Persiani, C.G.S. Huscher, L. Annino (Azienda Ospedaliera
S.Giovanni Addolorata, Rome, Italy) |
|
|
NEUROPROTECTIVE
EFFECT OF ERYTHROPOIETIN TREATMENT IN MYELOPATHY PATIENTS
S. Voulgaris, Ch. Kaliora, R. Zagorianakou, A. Chaidos, G. Hatzigiannakou,
K. Sfagos, K. Polyzoidis, K.L. Bourantas (University of Ioannina
Medical School, Ioannina, Greece) |
DC-DEVELOPED
FROM CD34+ CELLS USED AS VACCINE FOR POSSIBLE ANTICANCER THERAPY
P.G.M. Lazarova, M. LiJun, H. Hammerstad, G. Kvalheim, G. Gaudernack,
J. Nesland (District University Hospital “St.Anna”,
Varna, Bulgaria) |
PTH TREATMENT INDUCE ALTERATIONS
IN MURINE LONG-TERM BONE MARROW CULTURE
D.A. Svinareva, I.N. Nifontova, N.J. Drize (Hematological Scientific
Center, Moscow, Russian Federation) |
THE COMPARISON OF GENE EXPRESSION
OF UMBILICAL CORD VEIN AND BONE MARROW DERIVED MESENCHYMAL STEM
CELLS
R.A. Panepucci, J.L.C. Siufi, W.A. Silva-Jr, R. Proto-Siqueira,
L. Neder, M. Orellana, V. Rocha, D.T. Covas, M.A. Zago (University
of S. Paulo, Ribeirao Preto, Brazil) |
HEMATOPOIETIC STEM CELLS
AND MESENCHIMAL STEM CELLS IN LONG-TERM BONE MARROW CULTURES
OF TNF KNOCKOUT MICE
I.N. Nifontova, N.J. Drize (Hematological Scientific Center,
Moscow, Russian Federation) |
UNMANIPULATED ADULT LIVER
STEM CELLS FAILED TO SUSTAIN HEMATOPOIETIC RECONSTITUTION AFTER
TRANSPLANTATION IN NONHUMAN PRIMATES
M.D. Drouet, F. Norol, J.F. Mayol, J.F. Franetich, N. Grenier,
D. Mazier, C. Letoublon (CRSSA, La Tronche, France) |
BIOLOGY OF THE HEMOGENIC
MICROENVIRONMENT: THE OSTEO-HEMATON
I.B. Blazsek, E. Oberlin, B. Péault (Paul Brousse Hospital,
Villejuif, France) |
PROPERTIES OF IMMATURE HUMAN
MESENCHYMAL STEM CELLS AS PUTATIVE OMPONENT OF THE IN VIVO NICHE
OF HEMATOPOIETIC STEM CELLS
S. Gottschling, V. Eckstein, A. Jonas, U. Krause, A. Seckinger,
R. Saffrich, M. Uhrig, K. Miesala, A.D. Ho (University Hospital
Heidelberg, Heidelberg, Germany) |
COMPARATIVE ANALYSIS OF CHONDROCYTES
ISOLATED FROM HUMAN CARTILAGE AND DERIVED FROM HUMAN MESENCHYMAL
STEM CELLS
V. Paunescu, G. Tanasie, I.R. Siska, C. Tatu, C. Bunu, E. Suciu,
D. Szilagy, R. Cioaca (University of Medicine and Pharmacy,
Timisoara, Romania)
|
|
EVALUATION OF
CORD BLOOD FOR QUANTITATION OF HAEMATOPOIETIC PROGENITOR CELLS
N. Soyano, A.E. Soyano, A. Müller, B. Ponte, J. López
Mora, B. Martínez, F. Guevara, C. Landolfi, E. Romano
(I.V.I.C., Caracas, Venezuela) |
THE ROLE OF ONCOSTATIN M
IN FETAL HAEMOPOIESIS
J. de la Fuente, S. Boyce, J. Chan, K. O’Donoghue, S.
Kumar, N.M. Fisk, I. Roberts (Imperial College, London, United
Kingdom) |
GENERATION AND CHARACTERISATION
OF A NOVEL MULTIPOTENTIAL MURINE HEMATOPOIETIC PROGENITOR CELL
LINE WITH DC-DIFFERENTIATION POTENTIAL USING NOTCH-1 GENE TRANSFER
C. Klein, C. Rathinam, C. Rudolph, B. Schlegelberger, C. Klein
(Medical School Hannover, Hannover, Germany) |
IMMUNOPHENOTYPE OF CD34+
CELLS FROM PLACENTAL/ UMBILICAL CORD BLOOD AFTER CULTURE
P. Pranke, J. Hendrikx, G. Debnath, G. Alespeiti, P. Rubinstein,
N. Nardi, J. Visser (New York Blood Center/US and UFRGS, PUC,
Porto Alegre, Brazil)
|
CHROMOSOMAL ABERRATION
OF THE 11Q22-25 BANDS WITH AND WITHOUT MLL GENE REARRANGEMENT:
ANALYSIS OF 378 ACUTE LEUKEMIA PATIENTS
M.C. Cox, P. Panetta, F. Lo-Coco, G. Del Poeta, A. Venditti,
L. Maurillo, M.I. Del Principe, A. Mauriello, L. Anemona, A.
Bruno, C. Mazzone, P. Palombo, S. Amadori (S. Eugenio Tor Vergata,
Rome, Italy) |
GEOGRAPHICAL DIFFERENCES
IN THE INCIDENCE OF T(15;17) AND T(8;21) IN SPAIN.
M. Sierra, A. Alonso, J.M. Hernandez Rivas, M.D. Odero, B. Gonzalez,
I. Lahortiga, J.J. Perez, N.C. Gutierrez, M.J. Calasanz, J.F.
San Miguel (Hospital Clinico Universitario, Salamanca, Spain) |
FISH ANALYSIS OF 26 PATIENTS
WITH HEMATOLOGICAL NEOPLASIAS AND 1P36 REARRANGEMENTS ALLOWS
TO DEFINE A CLUSTER OF 2.5 MB INCLUDED IN THE MINIMAL REGION
DELETED IN THE 1P36 DELETION SYNDROME
I.L. Lahortiga, I. Vazquez, E. Belloni, J.P. Roman, P. Gasparini,
F.J. Novo, X. Agirre, J.L. Vizmanos, M. Valgañon, M.J.
Larrayoz, P.G. Pelicci, J.M. Hernandez, M.J. Calasanz, M.D.
Odero (University of Navarra, Pamplona, Spain) |
ACTIVE MUTATIONS OF C-KIT
IN T(8;21) ACUTE MYELOID LEUKEMIA; DISTINCT CHARACTERISTICS,
PROGNOSTIC SIGNIFICANCE, AND RESPONSE TO STI571
F.R.L.V. Lorenzo, K. Nishii, E. Usui, N. Katayama, H. Shiku
(Mie University School of Medicine, Tsu, Japan) |
|
|
ARRAY CGH STUDY
IN PATIENTS WITH ACUTE LEUKEMIA WITH NORMAL KARYOTYPE
M. Jarosova, H. Pospisilova, M. Divoka, M. Holzerova, I. Lakoma,
T. Papajik, A. Novosadova, T. Szotkowski, Z. Pikalova, V. Mihal,
B. Blazek, K. Indrak (University Hospital, Olomouc, Czech Republic) |
SUPERIORITY OF COMBINED BROAD
MOLECULAR SCREENING AND CYTOGENETICS IN DIAGNOSIS OF ACUTE LEUKEMIAS
S. Meyer-Monard, M. Jotterand, V. Parlier, J.R. Passweg, D.
Mühlematter, U. Hess, M. Bargetzi, T. Kühne, A. Gratwohl,
A. Tichelli (University Hospitals Basel, Basel, Switzerland) |
UNREARRANGED MLL GENE AMPLIFICATION
IN THREE CASES OF ACUTE MYELOYD LEUKEMIA (AML)
J.C. Pajuelo Gamez, J. Cervera, M.Z. Garcia-Casado, C. Garcia,
A. Valencia, P. Bolufer, E. Barragan, S. Cantero, M.J. Remigia,
M.L. Marty, M.A. Sanz (Hospital Universitario “La Fe”,
Valencia, Spain) |
DER(17)T(5;17) AND P53 GENE
MUTATIONS IN SECONDARY ACUTE LEUKEMIAS
P. Scaravaglio, A. Serra, E. Giugliano, G. Rege Cambrin, M.
Fimognari, M. Bonferroni, F. Locatelli, G. Saglio (S. Luigi
Hospital, Orbassano (Torino), Italy) |
A NOVEL CHROMOSOMAL TRANSLOCATION
T(3;7)(Q26;Q21) IN MYELOID LEUKEMIA RESULTING IN OVEREXPRESSION
OF EVI1
C.T. Storlazzi, L. Anelli, F. Albano, A. Zagaria, M. Ventura,
M. Rocchi, I. Panagopoulos, A. Pannunzio, E. Ottaviani, V. Liso,
G. Specchia (DAPEG-Section of Genetics, Univ. of Bari, Bari,
Italy) |
DETECTION OF A CRYPTIC EVI1
GENE REARRANGEMENT USING A VALIDATED PROBE SET FOR INTERPHASE
FISH
B. Cauwelier, B. Poppe, N. Yigit, A. De Paepe, Y. Benoit, N.
Dastugue, F. Speleman (University Hospital Ghent, Ghent, Belgium)
|
CRYPTIC INSERTION LEADING
TO NUP98/NSD1 CHIMERIC TRANCRIPT IN MYELOID MALIGNANCY
R. La Starza, P. Gorello, R. Rosati, A. Riezzo, B. Crescenzi,
M.F. Martelli, C. Mecucci (Policlinico Monteluce, Perugia, Italy) |
BREAKPOINT RESTRICTION AND
BONE MARROW LINEAGE AFFILIATION OF A COMPLEX CHROMOSOME REARRANGEMENT
INCLUDING THE ETV6-PDGFRΒ FUSION GENE
B. Crescenzi, R. La Starza, C. Nozzoli, S. Ciolli, D. Beacci,
M.F. Martelli, C. Mecucci (Institute of Hematology, Perugia,
Italy)
|
INCREASED RISK
FOR ACUTE LEUKEMIA IN INDIVIDUALS WITH GLUTATHIONE M1 (GSTM1)
AND T1 (GSTT1) GENE DEFECT
S. Tsabouri, I. Georgiou, S. Tsiara, K.L. Bourantas (University
of Ioannina Medical School, Ioannina, Greece) |
|
AML1 GENE REARRANGEMENTS
IN RADIATION-ASSOCIATED ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC
SYNDROME
S.V. Klymenko, M.J. Atkinson, V.G. Bebeshko, D.A. Bazyka, K.
Bink,
I.V. Dmitrenko, I.V. Abramenko, N. Bilous, H. Zitzelsberger,
M. Rosemann (Research Centre for Radiation Medicine, Kyiv, Ukraine) |
COMPARISON OF A MULTIPLEX
RT-PCR ASSAY WITH CYTOGENETIC ANALYSES IN ADULT HEMATOLOGIC
NEOPLASMS
O. Zach, B. Kessler, M. Stammler, M. Girschikofsky, O. Krieger,
H. Kasparu, O.A. Haas, D. Lutz (Elisabethinen Hospital, Linz,
Austria) |
PROGNOSTIC SIGNIFICANCE OF
STRUCTURAL CHROMOSOMAL REARRANGEMENTS IN CHILDREN WITH ACUTE
LYMPHOBLASTIC LEUKEMIA (ALL) AND HIGH HYPERDIPLOIDY
Z. Zemanova, K. Michalova, L. Sindelarova, L. Babicka, J. Brezinova,
S. Ransdorfova, P. Smisek, J. Stary (General Faculty Hospital,
Prague, Czech Republic) |
DYNAMICS OF TELOMERASE ACTIVITY
AND EXPRESSION OF THE HTERT GENE IN MYELODYSPLASTIC SYNDROMES
AND ACUTE LEUKEMIA
H. Zizkova, R. Dvorakova, S. Zilovcova, D. Brezinova, J. Cermak,
J. Stary, Z. Sieglova (Institute of Haematology and Blood Trans,
Prague, Czech Republic) |
INFLUENCE OF THE GSTM1 NULL
GENOTYPE IN THE RISK OF ACUTE MYELOID LEUKAEMIA AND NEUTROPENIA
DUE TO CHRONIC EXPOSURE TO CHEMICAL AGENTS
H. Nascimento, M.T. Teori, V.R. Arruda, S.T.O. Saad, I. Lorand-Metze,
F.F. Costa, C.S.P. Lima (State University of Campinas, Campinas,
Brazil) |
GENE EXPRESSION PROFILE OF
ACUTE MYELOID LEUKEMIA (AML) CASES WITH T(8;16)(P11;P13) AND
MYST3/CREBBP REARRANGEMENT
M. Camos, J. Esteve, P. Jares, D. Colomer, M. Rozman, N. Villamor,
D. Costa, F. Gomis, E. Campo, E. Montserrat (Hospital Clinic,
Barcelona, Spain) |
ANALYSIS OF THE EXPRESSION
OF 11Q23/MLL ABNORMAL FUSION TRANSCRIPTS IN ACUTE LEUKEMIA:
MULTI-CENTRE PERFORMANCE EVALUATION OF THE MLL FUSIONCHIPTM
T. Koki, C.J. Harrison, N. Maroc, A. Koki, A. Morel, M. Griffiths,
G. Mitterbauer-Hohendanner, S.A. Shurtleff, V. Fert, F. Hermitte,
V. Casteras (Ipsogen SAS, Marseille, France) |
INCIDENCE AND SIGNIFICANCE
OF MLL AMPLIFICATION DETECTED BY FISH IN ACUTE MYELOID LEUKEMIA
E. Giugliano, P. Scaravaglio, G. Rege Cambrin, M. Mancini, M.
Nanni, M. Fimognari, D. Diverio, F. Lo Coco, G. Saglio (S. Luigi
Hospital, Orbassano (Torino), Italy) |
|
|
ADDITIONAL CHROMOSOMAL
ABNORMALITIES IN CML PATIENTS TREATED WITH GLIVEC (CYTOGENETIC
AND MOLECULAR CYTOGENETIC STUDY OF 72 CASES)
M. Holzerova, M. Jarosova, E. Faber, H. Pospisilova, M. Priwitzerova,
I. Lakoma, J. Nausova, V. Divoky, M. Divoka, J. Voglova, K.
Indrak (University Hospital, Olomouc, Czech Republic) |
ASSESSMENT OF ETV6 GENE INVOLVEMENT
BY FLUORESCENCE IN SITU HYBRIDIZATION IN THREE NOVEL CHROMOSOME
12P REARRANGEMENTS IN HAEMATOLOGICAL MALIGNANCIES
M. Vieira, B. Marques, C. Cavaleiro, A.P. Ambrósio, M.
Jorge, H. Alaiz, J. Diamond, A. Neto, C. Santos, E.C. Júnior,
J.M. Pereira, M.G. Boavida (Instituto Nacional de Saúde,
Lisboa, Portugal) |
HAPLOTYPES LINKED
TO THE BETA S GENE IN SICKLE CELL ANEMIA PATIENTS FROM SOUTHERN
IRAN
Z. Rahimi, A. Merat, M. Haghshenass, N. Gerard, R. Krishnamoorthy,
R.L. Nagel (Kermanshah Univ. of Medical Sciences, Kermanshah,
Iran) |
MICROANGIOPATHIC HAEMOLYTIC
ANAEMIA IN SICKLE CELL DISEASE
D.K. Shome, A. Al Ajmi, F. Ali Darwish, K. Ravishekhar, A. Zaman,
N. Malik (Salmaniya Medical Complex, Manama, Bahrain) |
XMN I SITE POLYMORPHISM 5’
TO GAMA G IN SICKLE CELL DISEASE IN SOUTHERN IRAN
Z. Rahimi, A. Merat, M. Haghshenass, M. Karimi, N. Gerard, R.
Krishnamoorthy, R.L. Nagel (Kermanshah University, Kermanshah,
Iran) |
A NEW VARIANT OF GLUCOSE
PHOSPHATE ISOMERASE (GPI) (G145C/C921A) ASSOCIATED WITH SEVERE
HEMOLYTIC ANEMIA
E. Fermo, C. Vercellati, P. Bianchi, M.G. Mariani, A. Marcello,
A. De Fanti, G. Izzi, A. Zanella (IRCCS Ospedale Maggiore Milano,
Milan, Italy) |
DIAGNOSTIC AND ANEMIA-ASSOCIATED
ABERRATIONS OF RED BLOOD CELL MEMBRANE PROTEINS IN HEREDITARY
SPHEROCYTOSIS AND MILD THALASSEMIA
M.H. Antonelou, I.S. Papassideri, F.J. Karababa, A. Loutradi,
L.H. Margaritis (University of Athens, Faculty of Biology, Athens,
Greece) |
IMPAIRED PROLIFERATION AND
TRANSLATION IN DIAMONDBLACKFAN ANEMIA PATIENTS
J.C. Cmejlova, L. Dolezalova, D. Pospisilova, R. Cmejla (Institute
of
Hematology and Blood Transf, Prague, Czech Republic) |
CHARACTERIZATION OF A PYRIMIDIN
5’ NUCLEOTIDASE MUTANT FORM (G241R) CAUSING HEREDITARY
HEMOLYTIC ANEMIA.
L.R. Chiarelli, A. Mattevi, A. Galizzi, P. Iadarola, E. Fermo,
P. Bianchi, A. Zanella, G. Valentini (Università di Pavia,
Pavia, Italy) |
|
THE EFFCT OF
PROLACTIN ON THE PROLIFERATION AND DIFFERENTIATION OF ERYTHROID
PROGENITORS FROM HEMATOPOIETIC STEM CELLS IN DIAMOND-BLACKFAN
ANEMIA.
H. Kawasaki, Y. Noda, T. Nakano, Y. Kobayashi, K. Tsuji (Institute
of Medical Science, Univ Tokyo, Tokyo, Japan) |
A FAMILY WITH SECONDARY AND
CONGENITAL POLYCYTHEMIA: PROBABLE INVOLVEMENT OF O2 SENSOR PATHWAY
J. del Río Garma, L. Kun, R. Kralovics, R. Skoda (Hospital
da Barbanza, Ribeira-la Coruña, Spain) |
THE FREQUENCY AND MOLECULAR
GENETICS OF ERYTHROCYE G6PD DEFICIENCY IN ZANJAN CITY (NORTHWEST
IRAN)
Y. Mortazavi, A.R. Esmaeilzadeh, S. Kalantari (Zanjan Medical
School, Zanjan, Iran) |
MOLECULAR ANALYSIS OF FERROCHELATASE
GENE IN ITALIAN PATIENTS WITH ERYTHROPOIETIC PROTOPORPHYRIA
M.D. Cappellini, E. Di Pierro, V. Moriondo, L. Perego, D. Tavazzi,
P. Bonara (Ospedale Maggiore Policlinico, Milano, Italy) |
DIAGNOSTIC TOOLS IN CRYOHYDROCYTOSIS
DEMONSTRATED IN A PATIENT WITH A SPONTANEOUS MUTATION
J.S. Goede, G.W. Stewart, R. Rüegg, J. Fehr, H.U. Lutz
(University Hospital Zürich, Zürich, Switzerland)
|
PRELIMINARY REPORT
ON THE STUDY ON HEPATITIS C TREATMENT USING RIBAVIRIN AND PEGYLATED
INTERFERON IN THALASSEMIA PATIENTS (SCRIPT)
A. Sharara, S. Ghorra, A. Inati, E. Aoun, M. Taha, S. Koussa,
A. Taher (American University of Beirut, Beirut, Lebanon) |
THE -195 C>G MUTATION
IN THE A-GAMMA-GLOBIN GENE AMELIORATES THE HETEROZYGOUS BETA-THALASSAEMIA
PHENOTYPE
P. Faustino, C. Ferreira, M.C. Silva, A. Miranda, I. Picanço,
R. Martins, M.T. Seixas, L. Romão (Inst. Nacional Saúde
Dr Ricardo Jorge, Lisboa, Portugal) |
NTBI VALUES IN THALASSAEMIA
PATIENTS ON COMBINED CHELATION (DFO+L1) TREATMENT OR ON MONOTHERAPY
(DFO OR L1)
A. Meo, L. Duca, M.A. La Rosa, I. Nava, A. Ruggeri, L. Zanghi,
A. Crifò, M.D. Cappellini (Ospedale G. Martino Policlinico,
Messina, Italy) |
COMPARISON BETWEEN DESFERRIOXAMINE
AND PROSPECTIVE COMBINED THERAPY WITH DESFERRIOXAMINE AND DEFERIPRONE
IN BETA THALASSEMIA MAJOR PATIENTS WITH IRON OVERLOAD.
V. Pathare Anil, A.V. Pathare, S. AlKindi, D. Dennison, S. Daar
(Sultan Qaboos University Hospital, Muscat, Oman) |
|
|
STUDY OF IRON
OVERLOAD MEASURED WITH MAGNETIC RESONANCE IMAGING (M.R.I.) IN
PATIENTS WITH B-THALASSAEMIA COMPARED TO CHELATION THERAPY
V.P. Perifanis, A. Koussi, A. Christoforides, J. Tsatra, E.
Vlachaki, J. Tsitourides, M. Athanassiou-Metaxa (Hippokration
General Hospital,
Thessaloniki, Greece) |
RARE NEUTRAL BETA CHAIN HAEMOGLOBIN
VARIANTS DETECTED AND CHARACTERIZED BY REVERSED PHASE HIGH PERFORMANCE
LIQUID CHROMATOGRAPHY IN THE PORTUGUESE POPULATION
A. Miranda, P. Faustino, V. Almendra, M. Manso, M.C. Silva,
C. Ferreira, I. Picanço, M.T. Seixas (Inst. Nacional
Saúde Dr. Ricardo Jorge, Lisboa, Portugal) |
COINHERITANCE OF BETA-0 MUTATIONS
AND TRIPLICATED ALPHAGLOBIN GENES: PHENOTYPICAL EXPRESSION IN
ADULT LIFE.
M.D. Cappellini, C. Refaldi, M. Cerino, D. Bignamini, E. Volpato,
G. Fiorelli (Ospedale Maggiore Policlinico, Milano, Italy) |
HAPLOTYPE DIVERSITY OF BETA-GLOBIN
GENES IN BETATHALASSEMIA CARRIERS OF SERBIAN DESCENT
S. Pavlovic, J. Urosevic, J. Poznanic, L. Perisic, B. Petrucev,
N. Tosic, L. Krivokapic Dokmanovic, D. Janic, M. Cvorkov Drazic,
G. Bunjevacki (Inst Mol Gen and Gen Eng (IMGGE), Belgrade, Serbia) |
TOLERABILITY AND EFFICACY
OF LONG TERM COMBINED THERAPY OF DEFERIPRONE AND DESFERRIOXAMINE
IN PATIENTS WITH THALASSEMIA MAJOR
V. Ladis, A. Kattamis, K. Drakaki, I. Kaloumenou, A. Galani,
H. Berdousi, C. Kattamis (‘Aghia Sophia’ Children’s
Hospital, Athens, Greece) |
THE FIRST IVS2 SPLICE DONOR
SITE MUTATION IN THE ALPHA2 GLOBIN GENE (IVS-II-2 T>A) ASSOCIATED
WITH AN ALPHATHALASSEMIA PHENOTYPE.
C.L. Harteveld, M.C.W. Jebbink, P. van Delft, N. Akkermans,
S. Arkesteijn, P.C. Giordano (Leiden University Medical Center,
Leiden, The Netherlands) |
MAGNETIC RESONANCE IMAGING
(MRI) IN THE EVALUATION OF IRON OVERLOAD IN PATIENTS WITH BETA
THALASSEMIA AND SICKLE CELL DISEASE
E. Voskaridou, M. Douskou, E. Terpos, I. Papassotiriou, A. Stamoulakatou,
A. Ourailidis, A. Loutradi, D. Loukopoulos (Thalassemia Center,
Laikon Gnrl Hospital, Athens, Greece) |
|
|
